

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Estrogenic activity of biological samples as a biomarker

This is a pre print version of the following article:

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/1764940> since 2020-12-22T13:35:54Z

Published version:

DOI:10.1016/j.scitotenv.2020.140050

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

1 **ESTROGENIC ACTIVITY OF BIOLOGICAL SAMPLES AS A BIOMARKER**

2 Marta Gea^{a*}, Anna Toso^a, Tiziana Schilirò^a

3 *^aDepartment of Public Health and Pediatrics, University of Torino, Piazza Polonia 94 - 10126,*
4 *Torino, Italy;*

5

6 ***Corresponding author:**

7 **Marta Gea**

8 Department of Public Health and Pediatrics,

9 University of Torino,

10 Piazza Polonia, 94 - 10126, Torino, Italy,

11 Tel: +390116705821

12 e-mail address: marta.gea@unito.it

13

14

15

16

17

18

19

20

21

22

23

24

25

26 **Abbreviations**

27 BPA - bisphenol A

28 DCC - dextran-coated charcoal

29 E2 - 17 β -estradiol

30 EDCs - endocrine disrupting chemicals

31 EEQ - 17 β -estradiol equivalent quantity

32 ER - Estrogen receptor

33 FSH - Follicle-stimulating hormone

34 GH - Growth hormone

35 ISO - International Organization for Standardization

36 HELN - human uterine cervix carcinoma cells (HeLa) stably transfected with ERE- β Glob-Luc-SVNeo and pSG5ER α puro or pSG5ER β puro plasmids (HELN α or HELN β , respectively).

38 HPLC - high-performance liquid chromatography

39 LH - Luteinizing hormone

40 MELN - breast cancer cells (MCF-7) stably transfected with ERE- β Glob-Luc-SVNeo plasmid.

41 OECD - Organisation for Economic Co-operation and Development

42 PCBs - polychlorinated biphenyls

43 PFAA - perfluorinated alkyl acids

44 POPs - persistent organic pollutants

45 PP - precocious puberty

46 TEXB - total estrogenic burden

47

48

49

50

51 **ABSTRACT**

52 Biological assays can evaluate the cumulative effect of a mixture, considering
53 synergistic/antagonistic interactions and effects of unknown/unconsidered compounds.

54 Therefore, their application could increase in the next years also to analyse biological samples.

55 The aim of this review is to discuss the methodological approach and the application of
56 estrogenic activity assays in human biological samples. 75 research articles were analysed and
57 divided according to whether they used these assays: i) to quantify the level of estrogens and/or
58 as a biomarker of estrogenic status ii) as a biomarker of exposure to endocrine disrupting
59 chemicals (EDCs).

60 For the first purpose, some authors extracted biological samples while others tested them
61 directly without any treatment. The study of these methodologies outlined that the methodology
62 applied influenced the specificity of analysis. The estrogenic activity biomarker was used to
63 analyse physiological variations of estrogens, pediatric diseases, hormone-dependent diseases
64 and estrogen suppression/enhancement after pharmaceutical treatments.

65 For the second purpose, some authors extracted samples while others tested them directly, some
66 authors divided endogenous estrogens from xenoestrogens while others tested samples without
67 separation. The analysis of these methodologies outlined some limitations related to the
68 efficiency of extraction and the incorrect separation of some compounds. The studies which
69 applied this EDC biomarker showed that it was correlated with some EDCs, it varied according
70 to the exposure of the population and it allowed the identification of some relationships
71 between EDC exposure and breast cancer, type 1 diabetes and adverse health effects on
72 children.

73 In conclusion, the estrogenic activity of biological samples can be a useful tool: to quantify low
74 levels of 17β -estradiol, to assess the combined effect of endogenous estrogens and
75 xenoestrogens, to estimate the estrogenic status providing considerable insight into

76 physiological or pathological conditions, to evaluate EDC presence implementing the existing
77 knowledge about EDC exposure and adverse health effects.

78

79 **Keywords:** estrogenic activity, biological samples, EDC, exposure biomarker, hormone-
80 dependent diseases, adverse health effects.

81

82 **Contents**

83 1. Introduction

84 2. Assays for estrogenic activity evaluation

85 2.1. Ligand-binding assays

86 2.2. Gene reporter assays

87 2.3. Proliferation assays (E-screen assays)

88 3. Estrogenic activity as estrogen quantification and biomarker of estrogenic status: methodologies

89 4. Estrogenic activity as estrogen quantification and biomarker of estrogenic status: applications

90 4.1. Physiological variations of estrogens

91 4.2. Estrogenic activity and pediatric diseases

92 4.2.1. Female precocious puberty

93 4.2.2. Other female diseases

94 4.2.3. Sex differentiation disorders in males

95 4.3. Estrogenic activity and hormone-dependent diseases in women

96 4.4. Estrogen suppression/enhancement after pharmaceutical treatments

97 4.4.1. Females

98 4.4.2. Males

99 5. Estrogenic activity as a EDC biomarker: methodologies

100 6. Estrogenic activity as a EDC biomarker: applications

101 6.1. EDC biomarker and exposure to pesticides, polychlorinated biphenyls and perfluorinated
102 alkylacids

103 6.2. EDC exposed populations
104 6.3. EDC exposure and adult adverse health effects
105 6.4. Mother EDC exposure and child adverse health effects
106 7. Conclusion
107 8. Funding
108 9. Declaration of competing interest
109 10. References
110 11. Table captions
111

112 1. Introduction

113 The endocrine system is based on hormones, which are molecules produced by endocrine
114 glands, organs and tissues and released into the blood. Once they reach cells and tissues,
115 hormones can induce several effects through hormone receptors. Hormones are involved in
116 complex signalling pathways, which regulate numerous development stages of human and
117 animal life: foetal development, childhood and puberty. The endocrine system also controls
118 several functions in adulthood such as reproduction, metabolism and thermal regulation, and it
119 interacts with other systems such as nervous and immune systems (Bergman et al. 2013,
120 Demeneix and Slama 2019). Therefore, a correct functioning of the endocrine system is crucial
121 in order to ensure the correct regulation of numerous physiological processes and its
122 dysfunction or perturbation can lead to several adverse health effects such as malformations,
123 metabolic disorders, reduced fertility and cancer (Bergman et al. 2013, Kabir et al. 2015,
124 Pamplona-Silva et al. 2018).

125 Even if the endocrine system includes several different hormones, the scientific community
126 focused in particular on estrogens because of their peculiar characteristics. Estrogens exert a
127 crucial role in human organisms since they regulate menstrual/estrous reproductive cycles and
128 they are also involved in more complex mechanisms such as the physiology of reproductive

129 organs and tissues (e.g., breast, ovary and endometrium), lipid metabolism, protein synthesis
130 and diseases (e.g., cancer and neurodegenerative/cardiovascular diseases) (Kiyama and Wada-
131 Kiyama 2015). Moreover, estrogens play a critical role in the physiology and pathology of the
132 immune system, and therefore they can influence the onset and the progression of some
133 autoimmune diseases (Benagiano et al. 2019, Merrheim et al. 2020).

134 The most important endogenous estrogens are 17 β -estradiol (E2), estrone and estriol (Kiyama
135 and Wada-Kiyama 2015) and their actions occur at very low concentrations (Pamplona-Silva
136 et al. 2018).

137 Due to their key role in the organism, the evaluation of estrogen levels can be helpful to
138 understand and treat a wide range of physiological or clinical conditions in children as well as
139 adults (Rosner et al. 2013). The least invasive methods to estimate estrogen levels are indirect
140 methods which consist in tracking physiologic changes. These methods include monitoring
141 basal body temperature, using tests of urine to detect ovulation, examining vaginal discharge
142 and measuring other body changes, such as uterine length at pelvic sonography to evaluate
143 female pubertal status (Bellem et al. 2011, Paris et al. 2002). However, since they have a low
144 specificity and sensitivity, indirect methods are generally coupled with direct methods such as
145 immunoassays and spectrometry analysis which can quantify hormone levels in biological
146 samples (e.g. saliva, blood, urine) (Bellem et al. 2011). Immunoassays measure hormones
147 using the binding between antigen and antibody, which is amplified using different markers:
148 radioisotope, enzyme, fluorescent or chemiluminescent labels (radioimmunoassay, enzyme
149 immunoassay, fluorescence immunoassay, chemiluminescence immunoassay). Immunoassays
150 are generally considered to be quite specific, but their sensitivity is often insufficient to detect
151 low hormone levels and it seems that they tend to overestimate hormonal levels (Santen et al.
152 2008). Moreover they are unable to measure different estrogens simultaneously (Bellem et al.
153 2011) and they do not reflect the hormonal activity in the samples since they only quantify the

154 concentration of compounds that are structurally recognized by the antibody, thus neglecting
155 the overall activity induced by compounds with the same action mechanism (Widschwendter
156 et al. 2009). Mass spectrometry identifies and quantifies each chemical through its mass-to-
157 charge ratio after ionization (electron spray or electron impact ionization). Before the mass
158 spectrometry analysis, the sample is generally prepared using a separation technique (gas
159 chromatography or liquid chromatography). The tandem mass spectrometry, which is coupled
160 with spectral analysis in multiple rounds, is accepted as the golden standard for hormone assays
161 but it shows some limitations such as the expensive equipment needed and the technical
162 complexity of the analysis, which involves several steps and thus requires a long time (Bellem
163 et al. 2011). Immunoassays and mass spectrometry have been widely used for their specificity
164 since they quantify the concentrations of specific hormones. However, their high specificity
165 may oversimplify the physiological situation. The physiological hormonal activity is mainly
166 based on the effect of a specific hormone, but it can also be induced by other hormones,
167 hormone metabolites and growth factors. Also, it can be altered by exogenous substances.
168 Therefore, in recent years bioassays have been used for hormonal activity quantification by an
169 increasing number of authors. Bioassays are based on biological reactions that depend on the
170 presence or absence of the hormone, but also on the presence of other substances, which can
171 induce the same effect. For example, bioassays for estrogenic activity can detect the total
172 estrogenic effect in human biological samples: they measure the activity of E2 but are also able
173 to detect the activity induced by other estrogens such as estrone and estriol (Paris et al. 2002).
174 In addition to estrogens, a great number of exogenous compounds can exert and modulate the
175 estrogenic activity which can be measured by means of bioassays. These estrogenic compounds
176 are part of a group of substances called endocrine disrupting chemicals (EDCs). The World
177 Health Organization defined EDCs as “exogenous substances or mixtures that alter function(s)
178 of the endocrine system and consequently cause adverse health effects in an intact organism,

179 or its progeny, or (sub) populations” (Damstra et al. 2002). EDCs are a highly heterogeneous
180 group of natural (i.e., steroids and phytoestrogen) and synthesized chemicals (i.e., synthetic
181 chemicals, plastics, plasticizers, pesticides, pharmaceutical agents) (Diamanti-Kandarakis et
182 al. 2009, Kabir et al. 2015) which can interfere with the endocrine system in different ways:
183 first, they can act directly by binding to hormone receptors. In particular, agonist EDCs can
184 imitate hormones, thus producing over or under responses, while antagonist EDCs can block
185 the response. Second, EDCs can indirectly interact with receptors as they can interfere with the
186 synthesis, transport, metabolism and excretion of hormones (Hampl et al. 2016, Kabir et al.
187 2015). These contaminants are ubiquitous in the environment and human exposure to them
188 occurs in different ways, such as by inhalation (mainly in the working environment), ingestion
189 of contaminated food and/or water and dermal contact through personal care products (Kabir
190 et al. 2015). Since low doses of EDCs could be enough to induce effects - and exposure during
191 specific lifetime periods could induce permanent adverse effects - EDCs may represent an
192 alarming health and environmental problem.

193 In this context, the assessment of EDC exposure appears crucial in order to monitor populations
194 at higher risk of exposure and to understand the link between exposure and adverse health
195 effects. In biological samples concentrations of EDCs (e.g., bisphenol A (BPA), phthalates,
196 parabens, polychlorinated biphenyls (PCBs), perfluorinated compounds, polybrominated
197 diphenyl ethers) and metabolites of EDCs (e.g., metabolites of pyrethroids, insecticides,
198 pesticides, phthalates) have been used as conventional biomarkers of exposure (Calsolaro et al.
199 2017, Dziewirska et al. 2018, Hampl et al. 2016, Karwacka et al. 2019). However, since 1995
200 (Sonnenschein et al. 1995) some authors proposed novel biomarkers of exposure to EDCs,
201 which focus on detecting the biological effect of chemical compounds or metabolites, rather
202 than detecting the presence of the EDC itself. In particular, the estrogenic activity of biological
203 samples, measured with estrogenic activity assays, has been proposed and used as a novel

204 biomarker of exposure to EDCs. The main advantage of estrogenic activity assays is that they
205 can assess the total effect induced by multiple, exogenous chemicals with estrogenic activity
206 (xenoestrogens). Indeed, the chemical quantification of xenoestrogens provides an estimate of
207 the real exposure. However, the cumulative estrogenic activity of a mixture is not the sum of
208 the individual estrogenic activity of each xenoestrogen, since synergistic/antagonistic
209 interactions must be taken into account. Moreover, the chemical analysis of xenoestrogens only
210 takes into account specific known xenoestrogens and can not quantify the effect of unknown
211 or unevaluated compounds (Bicchi et al. 2009, Escher et al. 2018, Jarošová et al. 2014, Kase
212 et al. 2018, Könemann et al. 2018).

213 Consequently, the use of estrogenic activity assays in human biological samples may have two
214 main purposes, namely i) the assessment of total estrogenic effect to allow for the management
215 of a wide range of physiological or clinical conditions in children as well as in adults, and ii)
216 the improvement of the assessment of EDC exposure to allow for a better management of this
217 important health and environmental issue.

218 For the time being the development and application of estrogenic activity assays in human
219 biological samples do not seem to be widespread, compared to other experimental tools.
220 Nevertheless, their use could increase exponentially in the next years due to their versatility
221 and holistic approaches. It is thus much needed to gain additional knowledge of their
222 methodological approaches and applications relevant to them.

223 The aim of the present review is to discuss the methodological approaches and the applications
224 of estrogenic activity assays in human biological samples. A bibliographic research was
225 performed: 75 research articles were analysed in order to summarize the methods used to treat
226 biological samples and the results obtained.

227 The examined articles were divided into two categories, according to the use of estrogenic
228 activity: i) to quantify the level of estrogens and/or as a biomarker of estrogenic status, ii) as a
229 biomarker of exposure to EDCs.

230 To quantify the level of estrogens and/or as a biomarker of estrogenic status, the estrogenic
231 activity assays were applied in 38 of the analysed articles (table 1). Some authors mainly
232 considered estrogenic activity assays as tools for the evaluation of estrogen levels, specifically
233 for the evaluation of E2 levels (table 1, n° ref. 1- 8, 10-13, 18, 29, 32, 38). Other authors instead
234 used these assays for their ability to measure the total estrogenic effect defined as “evaluation
235 of estrogenic bioactivity” (table 1, n° ref. 9, 17). In this review, the application of estrogenic
236 activity assays was intended as a tool to detect the total estrogenic effect, meaning that it was
237 intended as a biomarker of “estrogenic status”, except for the articles published by Klein et al.
238 where it was intended as a tool for estrogen quantification. In these 38 studies, serum and
239 plasma were used as biological samples and they were analysed using gene reporter assays
240 (using mammalian and yeast cells) and proliferation assays (E-screen assays).

241 As biomarkers of exposure to EDCs, estrogenic activity assays were used in 37 of the analysed
242 articles (table 2). In these studies, the biomarker was defined as “assessment of total estrogenic
243 burden (TEXB)” (table 2, n° ref. 3), “total estrogenic xenobiotic burden” (table 2, n° ref. 4),
244 “total effective xenoestrogen burden” (table 2, n° ref. 7, 15, 16, 21, 22, 35) or “xenoestrogenic
245 activity” (table 2, n° ref. 11, 14, 32, 37). In this article the abbreviation “EDC biomarker” will
246 be used. In these 37 studies, serum, adipose tissue, placenta and milk were used as biological
247 samples and they were analysed using ligand-binding assays, gene reporter assays (using
248 mammalian and yeast cells) and proliferation assays (E-screen assays).

249

250

251

2. Assays for estrogenic activity evaluation

Assays for estrogenic activity evaluation have been described in recent review articles (Mueller 2004, Kiyama and Wada-Kiyama 2015, Wagner et al. 2017, Wangmo et al. 2018). For the assessment of the estrogenic activity in biological samples, three kinds of assays have been applied: ligand-binding assays, gene reporter assays and proliferation assays (E-screen assays). In the following sections the characteristics of these assays are briefly described considering their strengths/weaknesses (table 3) and their detection limits (table 4) in the assessment of estrogenic activity in biological samples. The assays validated by the Organisation for Economic Co-operation and Development (OECD) as tools to test potential EDC substances or by the International Organization for Standardization (ISO) as tools to assess water/waste water estrogenic activity are also listed.

2.1. Ligand-binding assays

Ligand-binding assays detect receptor–ligand interactions. These assays quantify the ability of a test chemical or a mixture to compete with E2 in binding to ER, and the result is often expressed as the concentration showing 50% displacement of E2 from receptor. The result can also be expressed as relative binding affinity with respect to E2 (Kiyama and Wada-Kiyama, 2015). Ligand-binding assays were initially performed using radioactive ligands, while, more recently, assays using non-radioactive ligands have been developed. Ligand-binding assays are able to detect the binding to ER of both agonist and antagonist substances without distinguishing between the two effects (Seifert et al. 1999). This characteristic is an advantage. Indeed, while in other estrogenic activity assays agonist and antagonist effects could compensate each other resulting in a null activity, in ligand-binding assays this compensatory effect can not occur. However, the same characteristic can be a disadvantage, since these assays are unable to assess the total estrogenic effect induced by the interaction of agonist and antagonist substances (Mueller 2004).

277 To assess the estrogenic activity in biological samples, a ligand-binding assay has been applied:
278 the enzyme linked receptor assay (Sapbamrer et al. 2010), a competitive enzyme immunoassay
279 which uses non-radioactive ligands. Moreover, the OECD has validated two ligand-binding
280 assays to screen and test potential EDC substances (OECD 2018), namely the Freyberger-
281 Wilson ER binding assay and the Chemical Evaluation and Research Institute (CERI) ER
282 binding assay (OECD n° 493 2015).

283 **2.2. Gene reporter assays**

284 Gene reporter assays consist of the transfection of a reporter construct into mammalian or yeast
285 cells. ER are transcription factors that induce the transcription of target genes after binding to
286 specific DNA sequences in their promoter; the reporter construct is made of these DNA
287 sequences linked to the gene of a measurable protein (for example the enzyme luciferase)
288 (Sonneveld et al. 2005). Gene reporter assays are able to quantify the total estrogenic effect
289 and are characterized by short incubation periods. However, the results of these assays can be
290 ambiguous when substances with overactivation effects are included in the analysed sample.

291 Gene reporter assays can be divided into two main categories. Some reporter gene assays are
292 performed on cells that already express ERs, while others are performed on cells that do not
293 express endogenous ERs. In the first category of gene reporter assays, cells are transfected with
294 an estrogen-inducible reporter gene. These cells can be transiently or stably transfected,
295 however, since stably transfected cells remain stable and ready for use, they are generally
296 preferred (Soto et al. 2006, Wangmo et al. 2018). In the second category of gene reporter
297 assays, cells are transfected with both an estrogen-inducible reporter gene and an ER
298 expression construct. Since these cells do not express other ERs, the advantage of these assays
299 is that they allow the evaluation of estrogenic activity in the samples distinguishing between
300 ER α and ER β estrogenic activity.

301 Numerous gene reporter assays have been applied for the assessment of estrogenic activity in
302 biological samples. Moreover, two gene reported assays have been validated by the OECD to
303 screen and test potential EDC substances (OECD 2018): the first uses ER α -HeLa-9903 cells
304 and the second uses VM7Luc4E2 cells (OECD n° 455 2016). Both assays use human cells
305 stably transfected with ER α , but the VM7Luc4E2 cells also express a minor amount of
306 endogenous ER β . As stated by the OECD, VM7Luc4E2 cells were originally designated as the
307 BG1Luc cells, however, in-depth analyses revealed that these cells were not the BG1 cells, but
308 instead a variant of the MCF-7 cells (OECD 2018). Recently, a gene reporter assay using stably
309 transfected human cells has also been described in the ISO 19040-3 (ISO 2018) for the
310 assessment of estrogenic activity in water and waste water. As for gene reported assays based
311 on yeasts, two assays, based on *Saccharomyces cerevisiae* or *Arxula adenivorans*, have been
312 described in the ISO 19040-1 (2018) and in the ISO 19040-2 (2018) as methods for the
313 assessment of estrogenic activity in water and waste water (Hettwer et al. 2018).

314 **2.3. Proliferation assays (E-screen assays)**

315 E-screen assays are proliferation tests. They measure the proliferative effect induced by
316 estrogens or estrogenic substances on estrogen-responsive cells. Proliferation is determined
317 through different procedures, including DNA staining and metabolic activity quantification.
318 The first E-screen assay was developed by Soto et al. (1997) using human breast cancer cells
319 (MCF-7), whose proliferation is mainly induced by the activation of ER α (Wagner et al. 2017).
320 Later on E-screen assays were also applied using MCF-7 sublines, such as the MCF-7 BUS, in
321 order to obtain a higher proliferative response (Martinez et al. 2016, Villalobos et al. 1995).
322 Many E-screen assays have been applied for the assessment of estrogenic activity in biological
323 samples, while they have not been reported by the OECD nor by the ISO (OECD 2018) to test
324 potential EDC substances or water/waste water estrogenic activity.

325

3. Estrogenic activity as estrogen quantification and biomarker of estrogenic

status: methodologies

The research group of Klein was the first to developed an estrogenic activity assay in biological samples (table 1, n° ref. 1). They developed an estrogenic activity assay as estrogen quantification using yeasts (i.e. a strain of *Saccaromyces cerevisiae*) in which the detection limit was 0.02 pg/mL, in order to overcome the lack of sensitivity of available assays for E2. Klein et al. (1994) treated serum samples performing a liquid-liquid extraction with ether and demonstrated that this assay was highly specific for E2 with low cross-reactivity for estrogen metabolites and other hormones, suggesting that this high specificity could be due to many factors, including the extraction of the samples.

The protocol of Klein et al. was mainly focused on measuring E2 and it was applied in many studies by the same research group (table 1, n°ref. 2-8, 10-13, 18, 22, 29, 32, 38).

Other authors applied extraction to biological samples before the analysis: in the studies of Pedersen et al. (2010) and Chamas et al. (2017) samples were extracted using a liquid-liquid extraction with methyl tert-butyl ether and diethyl ether respectively, while in the study of Kanaya et al. (2015) samples were extracted using a solid-phase extraction.

In 2002, the research group of Paris et al. developed an estrogenic activity assay for the determination of serum estrogenic activity using human uterine cervix carcinoma cells (HeLa) stably transfected with ERE- β Glob-Luc-SVNeo and pSG5ER α puro or pSG5ER β puro plasmids (HELN α or HELN β , respectively). In contrast to Klein et al. (1994), Paris et al. (2002) tested serum samples without extraction and without any other sample treatment to keep their conditions closer to those of their physiological status, since their aim was to develop a protocol for the assessment of the total estrogenic activity rather than for E2 quantification. Their protocol, based on HeLa cells, was subsequently applied by several authors (table 1, n° ref. 15, 17, 23, 24, 28) and it was also used by Séronie-Vivien et al. (2004) as a model to develop

351 another serum estrogenic activity assay based on breast cancer cells (MCF-7) stably transfected
352 with ERE- β Glob-Luc-SVNeo plasmid (MELN).

353 Other 11 articles reported in this review treated biological samples without any extraction (table
354 1, n° ref. 16, 19, 20, 25, 26, 27, 30, 31, 34, 35, 37). In almost all protocols, samples were added
355 to culture medium without any treatment. In four studies, however, samples were filtered (pore
356 size 0.22 μ m) before being added to culture medium (table 1, n° ref. 20, 25, 30, 32) and an
357 aromatase inhibitor was added with a view to preventing the conversion of testosterone to E2
358 by aromatase in the cells (table 1, n° ref. 20). Biological samples were tested in one or in
359 different concentrations ranging from 1 to 20% in culture medium.

360 The analysis of samples without extraction could be influenced by the complexity of
361 serum/plasma samples, therefore some authors proposed different methodological approaches
362 in order to consider the variability of these samples.

363 The variability caused by serum components was considered by many authors in the
364 construction of the standard curve. In five studies, the standard curve was produced for each
365 sample and consisted of stripped serum from the same patient, to which incremental amounts
366 of E2 were added (table 1, n° ref. 9, 15, 17, 23, 24, 28). Séronie-Vivien et al. (2004) considered
367 this approach as essential when the assay was performed to quantify E2 in serum, because it
368 was useful to remove the interference due to serum compounds different from E2, which
369 modulate the estrogenic activity and differ from patient to patient. However, for the detection
370 of estrogenic activity unrelated to E2 serum concentration, Séronie-Vivien et al. (2004) stated
371 that a single standard curve could be performed using charcoal-stripped serum from a healthy
372 volunteer in order to take into account a “normal overall estrogenic (transcriptional) activity of
373 human serum”.

374 Similarly to Séronie-Vivien et al. (2004), other authors used a single standard curve for all
375 samples (table 1, n° ref. 19, 20, 25, 26, 27, 30, 31). The standard curve was generally

376 constructed by adding E2 to medium with charcoal-stripped serum/plasma at the same
377 concentration as the sample's one. For example, in the study of Lim et al. (2014a), samples
378 were tested at a concentration of 10% in medium and the standard curve was constructed by
379 adding E2 to 10% charcoal-stripped commercial human serum in medium.

380 A similar approach was adopted by Sonneveld et al. (2005) in order to test different
381 concentrations of serum samples (0-10%) avoiding the variability caused by serum
382 components. For this purpose, the authors maintained the final serum concentration at 10% by
383 supplementing lower percentages of the tested sera with charcoal-stripped bovine serum.

384 Data were usually expressed as E2 equivalent quantity (EEQ), which is the total concentration
385 of estrogenic active compounds normalised to the E2. However, Martínez et al. (2016)
386 presented the results as estrogenic activity in comparison with a standard serum pool. In this
387 study, each serum sample was tested with 0.5% serum pool, which was used as a reference
388 standard to normalize the results. Other studies did not specify any peculiar approach to
389 evaluate the results (table 1, n° ref. 35, 37).

390 Like many hormones, estrogenic activity has a circadian rhythm, with nocturnal and early
391 morning rises (Janfaza et al. 2006, Li et al. 2009). For this reason, some authors pointed out
392 that they collected fasting blood samples during specific hours of the day, especially in the
393 morning (table 1, n° ref. 3, 4, 5, 6, 7, 8, 10, 12, 13, 18, 21, 32, 34, 35, 38).

394

395 **4. Estrogenic activity as estrogen quantification and biomarker of estrogenic** 396 **status: applications**

397 Estrogenic activity as estrogen quantification and biomarker of estrogenic status was applied:
398 i) to detect physiological variations of estrogens, ii) to study pediatric diseases, iii) to analyse
399 hormone-dependent diseases in women, iv) to evaluate estrogen suppression or enhancement
400 after pharmaceutical treatments.

4.1. Physiological variations of estrogens

401 Estrogenic activity assays were used to detect low concentrations of estrogens in children and
402 in post-menopausal women, since the sensitivity of other assays for E2 quantification was too
403 low.

404 Klein et al. (1994) measured physiological estrogen levels using an estrogenic activity assay in
405 prepubertal children, and found that the estrogen levels in prepubertal girls were higher than in
406 prepubertal boys, suggesting that these hormones may contribute to higher rates of skeletal
407 maturation, earlier puberty and earlier interruption of growth in girls compared to boys. The
408 same results were obtained in the study of Paris et al. (2002) using a different assay for the
409 evaluation of serum estrogenic activity. The role of estrogen levels in skeletal growth was
410 confirmed in another study (Klein et al. 1996): estrogen levels measured in healthy growing
411 boys were low throughout childhood, increased before puberty and rose steadily during
412 adolescence. Moreover, there was a relationship between estrogen levels and testosterone
413 concentrations and between estrogen levels and the time of peak growth velocity.

414 The physiological variations of estrogens were further evaluated by Janfaza et al. (2006) in 800
415 healthy children from birth to puberty. In the same study, the estrogen levels were measured
416 every hour for 24 hours in 55 children. Estrogen levels: (i) increased with age and pubertal
417 stage in both genders, (ii) showed a circadian rhythm with a nocturnal rise and (iii) were always
418 higher in girls than in boys.

419 The estrogenic activity/E2 level of prepubertal children was also evaluated to investigate the
420 relationship between estrogenic activity and adiposity. The first study on this topic was
421 performed by Klein et al. (1998b), whose results revealed that obese and nonobese children in
422 prepubertal or early pubertal stage showed similar circadian rhythms and similar E2 levels. E2
423 levels were not correlated with fat mass, body mass index, or arm fat, suggesting that E2 levels
424 are not directly correlated with markers of adiposity. Similar results were obtained by Larmore
425

426 et al. (2002), who did not find a significant correlation between estrogen levels and body mass
427 index or weight in their analysis of prepubertal and pubertal girls (obese and nonobese).
428 Furthermore, the study of Mesa Valencia et al. (2019) did not show any association between
429 estrogenic activity and markers of adiposity and metabolic and hormonal factors in prepubertal
430 girls, suggesting that estrogenic activity is not influenced by adiposity.

431 Estrogenic activity assays were also applied to detect low concentrations of
432 estrogens/estrogenic compounds in postmenopausal women. Wang et al. (2005) applied a gene
433 reporter assay using HeLa cells in samples of postmenopausal women, suggesting that such
434 assays could be useful not only to determine the concentration of E2, but also to assess the total
435 estrogenic activity.

436 Indeed, the authors claimed that the assay was not completely specific for E2 but seemed to
437 measure other biologically active estrogens as well. This hypothesis was supported by a
438 subsequent study (Wang et al. 2013), in which another estrogenic activity assay was applied
439 (E-screen assay). In this study, the serum estrogenic activity of postmenopausal women was
440 strongly associated with serum E2 levels, but it was also positively or negatively associated
441 with other serum molecules and women characteristics. These results suggested that the
442 estrogenic activity is influenced not only by endogenous estrogen levels but also by other
443 factors.

444 Finally, the estrogenic activity was evaluated in mother-child pairs. The study of Pedersen et
445 al. (2010) evaluated the estrogenic activity of both mother's and child's plasma (cord blood).
446 The results showed that the estrogenic activity of cord blood plasma was higher than the one
447 of mother plasma, and that the two parameters were loosely correlated. The authors also
448 suggested that the high estrogenic activity of cord blood probably reflected the elevated
449 estrogen production in the placenta and was not due to the presence of other estrogenic
450 compounds such as EDCs.

451 **4.2. Estrogenic activity and pediatric diseases**

452 Estrogenic activity assays were applied in order to analyse biological samples collected from
453 children and adolescents with pediatric diseases characterized by hormonal dysregulation:
454 precocious puberty, Turner's syndrome, type 1 diabetes and sex differentiation disorders.

455 **4.2.1. Female precocious puberty**

456 Precocious puberty (PP) is defined as the appearance of secondary sex characteristics in girls
457 aged under 8 years. PP is clinically distinguished between incomplete PP (premature thelarche,
458 premature pubarche, isolated menarche) and true PP (complete or central PP) (Sultan et al.
459 2018). Estrogenic activity assays have been used on both forms of PP by multiple studies.
460 Three studies focused on incomplete PP and specifically on premature thelarche, which refers
461 to the isolated breast development in girls aged under 8 without the development of any other
462 sexual characteristics. The first study (Klein et al. 1999) performed on young girls (less than 3
463 years of age) found that E2 levels in girls with premature thelarche were significantly higher
464 than in normal prepubertal girls. In the second study (Paris et al. 2013) information on parental
465 environmental/occupational exposure to EDCs during prenatal/postnatal patient life were
466 collected through surveys, in addition to estrogenic activity evaluation. The estrogenic activity
467 of girls with premature thelarche and whose parents had been exposed to EDCs was
468 significantly higher compared to the one of healthy girls. Moreover, it was significantly higher
469 compared to the estrogenic activity of girls with premature thelarche whose parents had not
470 been exposed to EDCs. This suggested that some patients may be affected by this condition
471 due to prenatal/postnatal EDC exposure. The third study (Pereira et al. 2015) investigated the
472 relationship between estrogen levels and risk of premature thelarche, assessing the estrogen
473 levels of prepubertal girls aged 7, who were monitored during the following years for the onset
474 of thelarche. The results showed that girls with estrogen levels over 5 pg/ml at 7 years had an
475 increased risk of presenting earlier thelarche onset.

476 E2 levels were evaluated using estrogenic activity assays also in girls affected by true PP. In
477 the study of Larmore et al. (2002), average E2 levels were higher in pubertal girls than in
478 prepubertal girls and in girls with PP. However, only E2 levels of normal pubertal and normal
479 prepubertal girls were statistically different. A high estrogenic activity was also detected in a
480 baby girl (4 months old) affected by precocious puberty (Gaspari et al. 2011b). Since high
481 concentrations of pesticides were detected in the plasma of both the patient and her parents, as
482 well as in the soil of their farm, the authors hypothesized a correlation between her precocious
483 puberty and exposure to pesticides.

484 **4.2.2. Other female diseases**

485 Wilson et al. (2003) compared the serum E2 levels in prepubertal girls affected by Turner's
486 syndrome with healthy prepubertal girls, and found that girls with Turner's syndrome had
487 significantly lower E2 levels. Martínez et al. (2016) compared the serum estrogenic activity of
488 post-menarcheal girls with type 1 diabetes to the estrogenic activity of normal post-menarcheal
489 girls, finding a statistically significant difference in the estrogenic activity of girls with type 1
490 diabetes compared to the control group. In these two studies, the application of estrogenic
491 activity assay allowed to demonstrate that the lack of normal ovarian function in girls with
492 Turner's syndrome is evident even before puberty, and that type 1 diabetes can also affect
493 estrogen metabolism.

494 **4.2.3. Sex differentiation disorders in males**

495 The study of Paris et al. (2006) found that the serum estrogenic activity of three children with
496 male pseudo-hermaphroditism was higher than in controls. This result, coupled with the
497 mother's exposure to environmental EDCs during pregnancy, suggested that ambiguous
498 genitalia could be related to foetal exposure to EDCs.

499 Similarly, the study of Gaspari et al. (2011a) found that the serum estrogenic activity of young
500 males with sex differentiation disorder was significantly higher in 11 males who had been

501 exposed to EDCs during the foetal period compared to 17 cases who had not been exposed and
502 compared to controls. Also, the estrogenic activity of patients who had not been exposed to
503 EDCs was not statistically different compared to controls, suggesting the possible relationship
504 between EDC exposure and sex differentiation disorder of some males.

505 **4.3. Estrogenic activity and hormone-dependent diseases in women**

506 Many studies investigated the relationship between estrogenic activity and breast cancer.
507 Séronie-Vivien et al. (2004) found that in controls the estrogenic activity was significantly
508 correlated with serum E2 concentration, while in advanced breast cancer patients it was less
509 correlated. In this study, the estrogenic activity was higher in controls than in patients, probably
510 because many pre-menopausal women were included in the control group.
511 Another study performed a similar comparison using a higher number of subjects
512 (Widschwendter et al. 2009). In contrast with the previous study, the estrogenic activity,
513 measured as estrogen receptor- α and estrogen receptor- β (ER α and ER β) transcriptional
514 activity, was higher in postmenopausal women with breast cancer compared to postmenopausal
515 controls, although no difference was observed in serum E2 levels between the two groups.
516 Moreover, this study suggested that estrogenic activity assays might predict ER-positive breast
517 cancer at the time of the diagnosis, since women with estrogenic activity (ER α and ER β) in the
518 highest quintile among controls had 7.57- and 10.14-fold risk of general and ER-positive breast
519 cancer respectively.

520 Recently, Fourkala et al. (2012) performed a case-control study nested in a cohort study
521 demonstrating that ER α transcriptional activity of serum collected more than two years before
522 diagnosis was independently associated with breast cancer risk, while ER α activity, collected
523 less than two years before diagnosis, and ER β activity were not. The association between ER α
524 transcriptional activity of serum, collected before diagnosis, and breast cancer risk was also
525 confirmed by the analysis of Asian women in the study of Lim et al. (2014a). Women in the

526 highest quartile for ER α activity had an odds ratio of 2.39 compared with those in the lowest
527 quartile. As reported also by Fourkala et al. (2012), cases and controls did not differ for ER β
528 transcriptional activity.

529 Considering the results of these studies, estrogenic activity assays seem to be a useful tool to
530 assess the risk assessment of breast cancer, since in most of the studies the serum estrogenic
531 transcriptional activity was associated with breast cancer risk.

532 Fejerman et al. (2016) measured the estrogenic activity of Latin-American women in order to
533 understand whether estrogenic activity may be related to higher breast cancer risk in US-born
534 Latinas compared to foreign-born. Using linear regression models, the authors found a positive
535 association between estrogenic activity and years of US residence (considering foreign-born
536 Latinas only), suggesting that the breast cancer risk observed in Latin-American women might
537 be related to the estrogenic activity.

538 Starting from this pilot study, Sanchez et al. (2019) assessed the association between estrogenic
539 activity, demographic factors and breast cancer risk factors in American women of different
540 racial/ethnic groups: Non-Latina Black, Non-Latina White and Latina women. Non-Latina
541 Black women showed the highest estrogenic activity, followed by Non-Latina White women,
542 while Latina women showed the lowest estrogenic activity. The multivariable analysis (which
543 included several independent variables) showed that the difference between Non-Latina White
544 and Latina women was statistically significant, as opposed to the difference between Non-
545 Latina Black and Non-Latina White women. The results of these two studies combined
546 suggested that the use of estrogenic activity assays might also provide explanation regarding
547 different breast cancer risk in different racial/ethnic groups living in the US.

548 The estrogenic activity of serum was also evaluated in relation to another hormone-dependent
549 disease in adults. Lim et al. (2012) considered the possible association between estrogenic
550 activity (measured as ER α transcriptional activity) and hip fracture risk in postmenopausal

551 Asian women. A high serum estrogenic activity, evaluated before hip fracture, was associated
552 with a reduced hip fracture risk. This reduction was still evident after adjustment for other
553 known risk factors of hip fracture were made, including age and body mass index. The results
554 suggested that a high estrogenic activity might prevent this hormone-dependent injury.
555 Finally, the same authors evaluated the influence of serum estrogenic activity (measured as
556 ER α and ER β transcriptional activity) on lung cancer survival in postmenopausal Asian women
557 (Lim et al. 2014b). Using regression analysis, they found that high ER β transcriptional activity
558 in sera was associated with a lower probability of lung cancer survival, while on the contrary
559 estrogen levels and ER α transcriptional activity were not associated with the probability of
560 survival. These results suggested that some serum activators of ER β may lower the probability
561 of lung cancer survival and that the evaluation of ER β estrogenic activity in sera might serve
562 as a prognostic marker to predict lung cancer survival.

563 **4.4. Estrogen suppression/enhancement after pharmaceutical treatments**

564 **4.4.1. Females**

565 The suppression of E2 levels after pharmaceutical treatments was tested in girls affected by
566 PP. In the study of Klein et al. (1998a), girls affected by PP were treated with different doses
567 of deslorelin for 9 months and serum E2 levels were evaluated using estrogenic activity assay.
568 The results showed that the suppression of E2 was dependent on the dose of deslorelin.
569 However, E2 concentrations were always above the E2 levels of normal prepubertal girls
570 regardless of the dose.

571 Other authors evaluated E2 levels using estrogenic activity assays after pharmaceutical
572 treatments in unhealthy girls. Taboada et al. (2011) assessed pharmacokinetics and
573 pharmacodynamics of the same form of E2 administered orally and transdermally to girls with
574 Turner's syndrome. Girls were treated for two weeks with either a high or a low dose of E2
575 administered orally or transdermally. This preliminary short-term study demonstrated that the

576 high dose of transdermal administration managed to restore the physiological levels of E2 and
577 estrone, while oral administrations increased estrone concentration compared to both
578 transdermal administration and controls regardless of the dose. High transdermal E2
579 administration proved to be the most effective way to make the estrogenic activity of the
580 patients the most similar to the estrogenic activity of controls.

581 This preliminary short-term study was carried forward by the subsequent study of Torres-
582 Santiago et al. (2013). The authors assessed the metabolic effects and body composition
583 changes in girls with Turner's syndrome treated with the same form of E2 given orally or
584 transdermally for a year. E2 doses were titrated in order to achieve E2 levels within the normal
585 range of menstruating adolescents. The two treatments induced similar effects on numerous
586 monitored parameters: follicle-stimulating hormone (FSH) and luteinizing hormone (LH)
587 concentrations, body composition (weight, body mass index, percentage of fat mass, fat-free
588 mass, abdominal fat), lipid concentrations and oxidation, resting energy expenditure rates and
589 bone mineral density. However, since the estrogenic activity of serum samples, estrone and
590 estrone sulfate concentrations were higher in girls treated orally with E2 than in girls treated
591 with transdermal E2 administration, the authors concluded that transdermal administration
592 might be more effective than oral administration in inducing a more physiological estrogenic
593 status in girls with Turner's syndrome.

594 Estrogenic activity assays were also used to test women after pharmaceutical treatments. The
595 first study to focus on women was the one of Klein et al. (1995), in which the E2 levels were
596 measured using a bioassay in women affected by breast cancer and treated with different doses
597 of an aromatase inhibitor for twelve weeks (100 µg/day - 5.0 mg/day of letrozole). The result
598 of the study demonstrated that all doses of the drug induced an equivalent suppression of E2
599 levels.

600 The second study on women tested the suppression and recovery of E2 after injection of a
601 potent gonadotropin-releasing hormone receptor agonist (leuprolide acetate) in healthy
602 volunteers (Larmore et al. 2000). Measured with an estrogenic activity assay, E2 levels were
603 significantly suppressed by week 3 and further suppressed by week 4 after one injection of
604 leuprolide acetate. E2 remained below postmenopausal levels for 5-8 weeks after one injection
605 and for 6 weeks after a second injection (4 weeks apart).

606 Finally, Santen et al. (2002) investigated the estrogenic activity of serum collected from
607 postmenopausal women affected by urogenital atrophy and treated with vaginal E2, in order to
608 determine the lowest dosage needed to reverse signs and symptoms of urogenital atrophy
609 without substantially increasing serum E2 levels. As measured by bioassay, a dose equal to 10
610 μg of vaginal E2 relieves the symptoms of urogenital atrophy and induces objective vaginal
611 changes without increasing serum E2 levels.

612 **4.4.2. Males**

613 E2 suppression can be induced in boys with severe growth retardation in order to delay puberty
614 and then the epiphyseal fusion, thus maximizing height potential. For this purpose, Mauras et
615 al. (2000) analysed the performance of anastrozole, a nonsteroidal aromatase inhibitor that
616 blocks the conversion of $\Delta 4$ -androstenedione to estrone and of testosterone to E2. The drug
617 was tested in healthy young boys and the results showed that E2 concentrations were
618 dramatically reduced after anastrozole administration. The drug seemed to be well tolerated
619 and safe, since the treatment did not affect body composition, protein kinetics/substrate
620 oxidation rates, muscle strength, and bone calcium metabolism. Based on these results, the
621 authors stated that anastrozole appears to be suitable to treat boys with growth retardation.

622 This hypothesis was further supported by the same authors in a subsequent study (Mauras et
623 al. 2004). In this study, growth hormone (GH) deficient boys were treated for 12 months with
624 GH (control group) or with GH and anastrozole in order to suppress estrogen production and

625 delay epiphyseal fusion. After the treatment, E2 concentrations decreased in boys treated with
626 anastrozole and increased in the control group. Testosterone levels were higher in boys treated
627 with anastrozole compared to control group. Although both treatments did not increase
628 predicted adult height, anastrozole treatment dramatically decreased estrogen concentrations
629 without effects on body composition, plasma lipids, and bone metabolism.

630 Estrogenic activity assays were also used to assess the effect of the decoction of a Chinese
631 medicinal plant (*Epimedium pubescens*), compared to the effect of a standard estrogenic
632 prodrug (estradiol valerate) generally used to counteract menopausal symptoms (Li et al. 2009).
633 The study was performed on male subjects in order to reduce the interference due to
634 endogenous estrogens, and the estrogenic activity was evaluated in serum using different assays
635 (ER α and ER β gene reporter assays and E-screen assay). Ingestion of the standard drug induced
636 a significant increase of serum estrogenic activity using all assays, while the plant decoction
637 only induced a small but significant increase of ER α transcriptional activity, suggesting that
638 the administration of this traditional decoction may not be suitable to counteract menopausal
639 symptoms.

640

641 **5. Estrogenic activity as a EDC biomarker: methodologies**

642 Human biological samples can contain endogenous steroidal estrogens, but also EDCs with
643 estrogenic activity called xenoestrogens, which can be introduced in the human body through
644 inhalation, ingestion of contaminated food/water, and dermal contact. Since the evaluation of
645 estrogenic activity through assays measures the effect induced by all estrogenic compounds,
646 the use of these methods alone is unable to determine whether a phenomenon is induced by
647 endogenous estrogens or xenoestrogens. Therefore, in order to use estrogenic activity assays
648 as a EDC biomarker, in most studies the biological samples were treated in order to remove
649 endogenous estrogens.

650 The studies of Sonnenschein et al. (1995) and Soto et al. (1997) are to our knowledge the first
651 ones that applied estrogenic activity assays as a biomarker. The protocol follows multiple
652 stages: (i) serum sample extraction, (ii) acid cleanup and (iii) separation of xenoestrogens from
653 endogenous estrogens by high-performance liquid chromatography (HPLC) in silica column
654 using the method proposed by Mendina and Sherman (1986). The separation is based on the
655 elution time from the HPLC column. Since xenoestrogens (estrogenic pesticides, PCBs,
656 hydroxylated PCBs, phenolic antioxidants and plasticizers) and endogenous estrogens have
657 different elution times, xenoestrogens can be collected during the first 10 minutes of elution.
658 However, some xenoestrogens, such as phytoestrogens, diethylstilbestrol and mycoestrogens
659 cannot be extracted through this technique, as their retention time is longer than 12 minutes
660 (Soto et al. 1997).

661 The protocol proposed by Sonnenschein et al. (1995) and optimized by Soto et al. (1997) was
662 further refined and modified by Rasmussen et al. (2003) by the introduction of solid-phase
663 extraction and a modified HPLC gradient, with elution of xenoestrogens within 5.5 minutes.
664 Rasmussen et al. (2003), who analysed serum samples from pregnant women, stated that two
665 subfractions of the extract collected during the first 5.5 minutes could contain pregnancy-
666 related hormones (5α - dihydroprogesterone and fatty acid esters of estrone or E2). These
667 subfractions (1.8 – 2.3 min and 3.8 – 4.3 min) were thus removed for the sake of analysis. In a
668 subsequent study, Andersen et al. (2007) collected the xenoestrogens during the first 8 minutes
669 in order to include more hydrophilic pesticides. However, they removed an additional
670 subfraction (6.2–7.1 min) to avoid pregnenolone. The protocol, improved by Rasmussen et al.
671 (2003), was applied in eight other studies (table 2, n° ref. 10, 11, 12, 13, 14, 19, 20, 27).

672 Starting from this protocol, which was focused mainly on the extraction of persistent EDCs,
673 Bjerregaard-Olesen et al. (2015) developed an extraction method for serum samples which was
674 optimized for perfluorinated alkyl acids (PFAA). As the previous one, this method is composed

675 by solid-phase extraction (water phase), liquid/liquid extraction (tetrahydrofuran/n-hexane)
676 and HPLC fractionation (extract collected between 22.01 and 26.00 min). However, since after
677 the HPLC fractionation estriol and estetrol are still present, this method also contains a weak
678 anion exchange extraction in order to remove these endogenous hormones from the final
679 extract. This protocol optimized for PFAA was subsequently applied in three studies (table 2,
680 n° ref. 33, 36, 37).

681 Recently, a third protocol with HPLC fractionation was developed in order to analyse human
682 serum samples (Pastor-Barriuso et al. 2016). In this protocol, the HPLC fractionation is
683 preceded by liquid-liquid and solid-phase extractions.

684 In 1997, the Spanish research group of Rivas and Olea (1997) published another methodology
685 to assess the estrogenic activity as a EDC exposure biomarker using adipose tissue samples
686 instead of serum samples. The authors proposed a protocol in which the adipose tissue was
687 dissolved in hexane and eluted with hexane in a glass column filled with Alumina Merck 90;
688 the eluate obtained was then concentrated and injected in HPLC for separation of
689 xenoestrogens from endogenous estrogens. The HPLC fractionation was performed using the
690 method previously proposed for serum samples (Sonnenschein et al. 1995). Three fractions
691 from HPLC were collected: α -fraction, during the first 11 minutes, containing xenoestrogens;
692 x-fraction from 11 to 13 minutes; β -fraction from 13 to 25 minutes containing endogenous
693 hormones. However, since additives and monomers from plastics (such as bisphenols) are
694 collected alongside endogenous hormones, their effect can not be evaluated analysing the
695 fraction of xenoestrogens.

696 This HPLC separation protocol was applied by some authors on human adipose tissues (table
697 2, n° ref. 4, 7, 8, 15, 16, 21, 26, 35), while others applied it on human placentas (table 2, n° ref.
698 16, 17, 22, 23, 25, 30, 31).

699 In contrast to previously reported studies, which used extraction and HPLC fractionation, two
700 articles (Natarajan et al. 2002, Sapbamer et al. 2010) separated endogenous estrogens by
701 xenoestrogens with two alternative methods. The former used polyclonal antibodies to
702 immunoprecipitate the endogenous estrogens (E2) and then separate them from the
703 xenoestrogens. In the latter dextran-coated charcoal (DCC) was used to remove all gonadal
704 hormones. The DCC is made from acid washed charcoal powder and dextran and it is generally
705 used to reduce the levels of estrogens in foetal bovine serum, producing the dextran coated-
706 charcoal stripped serum. However, it is important to bear in mind that, as reported by the
707 manufacturer's instructions (Sigma Product Information), although this treatment may reduce
708 the levels of estrogens in the sample it might not completely eliminate estrogens or any other
709 steroids from the serum.

710 Other studies did not apply any separation technique but extracted the biological sample and
711 tested the whole extract. In the study of Plíšková et al. (2005), half of a crude extract was used
712 for the determination of overall estrogenic activity, while the other half was placed on a sulfuric
713 acid-activated silica column, eluted with n-hexane: diethyl ether mixture, evaporated, and
714 redissolved in DMSO, in order to elute only persistent compounds (including PCBs,
715 polychlorinated dibenzo-p-dioxins and dibenzofurans).

716 In the studies of Arrebola et al. (2012, 2013), an evaluation without separation was performed
717 in order to assess the combined effect of endogenous estrogens and xenoestrogens, since the
718 estrogenic activity of the whole extract can be considered as a measure of the effect of complex
719 interactions among all estrogenic compounds (i.e. xenoestrogens and endogenous hormones).
720 However, the estrogenic effect of endogenous hormones may be underestimated using this
721 approach. Indeed, as specified by the same research group (Fernández et al. 2007a), this
722 protocol was developed to efficiently extract lipophilic xenoestrogens and, as such, it may not
723 be so effective to extract endogenous hormones. Nonylphenol, octylphenol and BPA, the most

724 polar xenoestrogens, may also be inefficiently extracted by increasing the under-estimation of
725 the interaction among estrogenic compounds within the sample (Fernández et al. 2007a).
726 Finally, some studies did not apply any separation techniques and did not extract biological
727 samples but tested them without any treatment as a EDC biomarker (Brouwers et al. 2011,
728 Kanno et al. 2007).

729

730 **6. Estrogenic activity as a EDC biomarker: applications**

731 The evaluation of estrogenic activity as a EDC biomarker might be a useful tool to understand
732 the relationship between emission, exposure, biological effects and health risks associated with
733 EDCs.

734 This evaluation can be used for EDC exposure assessment (Andersen et al. 2007) and it can be
735 considered as a biomarker of biological effective dose (Sonnenschein et al. 1995, Soto et al.
736 1997). However, some authors seem to apply the biomarker also as a biomarker of effect
737 (Bonefeld-Jørgensen 2014), as it can measure the effects induced on the organism by multiple
738 chemicals considering all the possible interactions among them.

739 **6.1. EDC biomarker and exposure to pesticides, polychlorinated biphenyls and** 740 **perfluorinated alkylacids**

741 Rivas et al. (2001) evaluated the estrogenic activity of adipose tissue extracts containing
742 xenoestrogens (HPLC fractionation technique) collected in 400 women as a EDC biomarker.
743 The concentrations of 16 organochlorine pesticides were also quantified in the extracts, but the
744 concentration of each pesticide was not correlated with the EDC biomarker. The authors
745 claimed that this finding could be due to the combined effect of pesticides and/or to the effect
746 of substances that had not been measured. A subsequent study of Fernández et al. (2004)
747 confirmed that the combined effect of compounds is difficult to predict considering the effect
748 of each one: the authors found that the estrogenic activity of a serum extract (consisting of

749 different extract fractions obtained with HPLC fractionation technique) rarely corresponded to
750 the sum of the estrogenic activity of each fractions.

751 In contrast with the results of Rivas et al. (2001), in the study of Andersen et al. (2007) the
752 estrogenic activity of serum extracts containing xenoestrogens (HPLC fractionation technique)
753 was significantly and positively associated with pesticide exposure evaluated through
754 interviews both with pregnant and non-pregnant women working in Danish greenhouses. The
755 results of this study also demonstrated that the EDC biomarker is representative of recent
756 exposures. Indeed, among pregnant women, the positive association was only significant for
757 those who had been working one week before the sampling, while no association was observed
758 for women working in the previous period.

759 A negative association between PCB exposure and estrogenic activity was observed by
760 Plíšková et al. (2005) who studied men living in a PCB polluted area and in a control
761 background area (different districts in eastern Slovakia). Serum extracts containing persistent
762 compounds (extraction technique optimized for persistent compounds) from people living in
763 the background area showed higher estrogenic activity, while extracts from the polluted area
764 showed an antiestrogenic activity. The association between PCB exposure and antiestrogenic
765 activity was also confirmed by the comparison between the total estrogenic activity and PCB
766 concentrations, since the estrogenic activity of the extracts containing endogenous estrogens
767 and persistent compounds (crude extracts) was lower in the samples with high PCB levels.
768 Since the levels of E2 decreased in the samples with high PCB levels, the authors stated that
769 exposure to high PCB levels might also affect concentration of E2 in blood, causing the
770 decrease of estrogenic activity and an overall antiestrogenic effect.

771 Kanno et al. (2007) studied the estrogenic activity of serum samples (without treatment)
772 collected from patients who underwent hemodialysis and peritoneal dialysis compared to a
773 control group. The patients' sera had higher levels of BPA compared to controls and they

774 induced a higher estrogenic activity compared to the activity expected for the measured BPA
775 levels. The authors discussed the results, claiming that the high level of BPA was probably due
776 to the release of BPA from the dialyzers to patient's serum and that the unexpectedly high
777 estrogenic activity could be due to the release of other EDCs, such as phthalate diesters in
778 patient's serum.

779 Brouwers et al. (2011) studied men with different EDC exposure levels and found that
780 occupational exposure to pesticides, disinfectants and exhaust fumes were associated with
781 increased plasma estrogenic activity (without treatment). Instead, body mass index, use of
782 personal care products and proximity to city centre were not associated with the EDC
783 biomarker.

784 However, the results of Kanno et al. (2007) and Brouwers et al. (2011) could have been
785 influenced by a possible interference of xenobiotics with endogenous estrogen levels, since the
786 authors used the estrogenic activity in total plasma/serum as a EDC biomarker without dividing
787 endogenous estrogens from xenoestrogens.

788 Finally, Bjerregaard-Olesen et al. (2016) studied the relationship between exposure to PFAAs
789 and estrogenic activity of serum extracts containing PFAAs (HPLC fractionation technique) in
790 pregnant women. Their study found positive linear associations between the estrogenic activity
791 and the PFAA serum levels but also inverse linear associations between extracts with an
792 antiestrogenic activity (when tested with E2) and PFAA serum levels.

793 **6.2. EDC exposed populations**

794 The EDC biomarker was used to study Nordic populations, which are considered to be highly
795 exposed to persistent organic pollutants (POPs) and EDCs, since numerous POPs (such as
796 PCBs, dioxins and organochlorine pesticides) are also classified as EDCs. Due to their
797 resistance to environmental degradation, POPs are transported to the Arctic by the atmosphere
798 and ocean currents; here, due to their chemical characteristics, they are bioaccumulated in the

799 adipose tissue of animals and then of humans through their diet. Nordic populations are
800 particularly exposed to POPs since their diet consists of a high intake of fish and marine animals
801 (seals, whales, polar bears, seabirds) and includes the consumption of tissues and organs that
802 contain animal fats where POPs are highly accumulated (liver, blubber, skin) (Bonefeld-
803 Jørgensen et al. 2010).

804 Rasmussen et al. (2003) studied the estrogenic activity of serum extracts containing
805 xenoestrogens (HPLC fractionation technique) collected from three groups of women: 30
806 pregnant Danish women (slightly exposed), 60 non-pregnant Danish women (slightly exposed)
807 and 211 pregnant Faroese women (highly exposed through diet), and found that the EDC
808 biomarker was higher in Faroese women compared to Danish women.

809 Other authors studied the Inuit Greenlandic populations as exposed populations, and compared
810 the Inuit men with European men from Sweden, Poland (Warsaw) and Ukraine (Kharkiv). The
811 results of the comparison showed that Inuit serum extracts containing xenoestrogens (HPLC
812 fractionation technique) induced no estrogenic activity but elicited an antagonistic effect when
813 the extracts were tested in combination with E2 (71% of samples) (Bonefeld-Jørgensen et al.
814 2006). Contrarily, some European extracts induced estrogenic activity and only a few extracts
815 elicited an antagonistic effect when tested with E2 (7-30% of samples). The EDC biomarker
816 was not strongly associated with serum concentration of POPs (Bonefeld-Jørgensen et al. 2006)
817 and no consistent association was found between the EDC biomarker and the adult semen
818 quality assessed as sperm concentration, motility and morphology (Toft et al. 2007). In addition
819 to lower estrogenic activity, Inuits were found to have lower sperm DNA damage, while in
820 Europeans the estrogenic activity was positively correlated with DNA damage, suggesting that
821 altered estrogenic activity together with genetic and/or nutrient factors may protect Inuits'
822 sperm DNA from damage (Long et al. 2007). Different correlations between sperm DNA

823 damage and the EDC biomarker were further showed when comparing Inuits and Europeans
824 using another assay (sperm chromatine structure assay) (Krüger et al. 2008b).
825 The EDC biomarker was also used to study differences among Inuit populations across
826 Greenland. The study of Krüger et al. (2008a) measured the estrogenic activity of serum
827 extracts (HPLC fractionation) in men and women from different Greenlandic districts (Nuuk,
828 Sisimiut and Qaanaaq) to evaluate associations between the EDC biomarker, POPs
829 concentrations (14 PCBs and 10 pesticides), and lifestyle characteristics. The EDC biomarker
830 showed different levels depending on districts and genders. In accordance with previous
831 studies, male and female serum extracts generally induced a decrease in estrogenic activity and
832 showed an antagonistic effect when the extracts were tested in combination with E2. Overall,
833 few correlations were observed between the EDC biomarker and concentrations of each PCB
834 and pesticide. A similar experimental study was performed in 2012 by the same authors
835 (Krüger et al. 2012) in other Greenlandic districts (Ittoqqortoormiit, Narsaq and Qeqertarsuaq).
836 The levels of the EDC biomarker were different depending on the district. The Ittoqqortoormiit
837 serum extracts contained high levels of POPs and elicited an antagonistic effect similar to the
838 extracts tested in the previous study (Nuuk, Sisimiut and Qaanaaq). On the contrary, a higher
839 agonistic effect was observed in Qeqertarsuaq and Narsaq extracts. As summarized by two
840 reviews (Bonfeld-Jørgensen 2010, Bonfeld-Jørgensen et al. 2014), the results of studies on
841 Greenlandic Inuit suggested that the EDC biomarker is negatively correlated with POPs and it
842 can be used as a biomarker in order to detect POP exposure.

843 **6.3. EDC exposure and adult adverse health effects**

844 The EDC biomarker was also applied to study the association with type 2 diabetes and breast
845 cancer.
846 Arrebola et al. (2013) applied the estrogenic activity measured in adipose tissues (extraction
847 technique) of adults from Southern Spain as pesticide and PCB exposure biomarker, in order

848 to evaluate the possible role of these substances for the onset of type 2 diabetes. In the study,
849 the concentrations of pesticides and PCBs in adipose tissue and serum were associated with
850 type 2 diabetes, while the EDC biomarker was not associated with the disease and did not
851 influence the effect of the substances on the disease, indicating that estrogenic activity may not
852 be a critical factor for the onset of diabetes.

853 Among the studies on breast cancer, Ibarluzea et al. (2004) evaluated the estrogenic activity of
854 two types of adipose tissue extracts (containing xenoestrogens and containing endogenous
855 estrogens- HPLC fractionation technique) and the concentration of 16 organochlorine
856 pesticides in the adipose tissue in a case-control study, comparing women who had just been
857 diagnosed with cancer and control women. No significant differences were observed in
858 concentrations of pesticides and in the estrogenic activity of extracts containing xenoestrogens
859 between the two groups. However, in women with a body mass index below the median
860 (especially for the postmenopausal group), the high estrogenic activity of extracts containing
861 xenoestrogens was associated with increased risk of breast cancer. The association was
862 detected only by considering the activity of extracts containing xenoestrogens, while no
863 association was found between breast cancer risk and the estrogenic activity of extracts
864 containing endogenous estrogens (Fernández et al. 2007b). This first evidence of a significant
865 association between the EDC biomarker and the risk of breast cancer was further investigated
866 considering potential confounders and covariates (Fernández et al. 2007a). In patients, the
867 estrogenic activity of adipose tissue extracts containing xenoestrogens (EDC biomarker)
868 (HPLC fractionation technique) was associated with age, family history of breast cancer,
869 lactation experience and smoking, while in controls it was only associated with age. Moreover,
870 in patients the estrogenic activity of adipose tissue extracts containing endogenous estrogens
871 (HPLC fractionation technique) was associated with age, educational level, age at menarche,
872 menopausal status, marital status, lactation experience and smoking, while in controls it was

873 only associated with menopausal status. Therefore, the analysis of confounders and covariates
874 showed that the EDC biomarker might also be sensitive to environmental, dietary, lifestyle,
875 genetic and reproductive factors.

876 A similar case-control study (Pastor-Barriuso et al. 2016) investigated the relationship between
877 the EDC biomarker and breast cancer risk using serum instead of adipose tissue samples. No
878 significant difference was observed in concentrations of each organohalogenated compound
879 (PCBs, hexachlorobenzene, p,p'-dichlorodiphenyldichloroethylene) between women with
880 breast cancer and controls. In contrast with the previous study, the estrogenic activity of both
881 types of extracts (containing xenoestrogens and containing endogenous estrogens -HPLC
882 fractionation technique) was higher in cases than in controls and the estrogenic activity
883 measured in serum extracts was not associated with potential confounders (e.g. age, body mass
884 index) except for geographical region. Nevertheless, in accordance with the previous study,
885 this study highlighted the importance of the EDC biomarker since it demonstrated a strong
886 positive association between the estrogenic activity of extracts containing xenoestrogens and
887 the risk of breast cancer. Moreover, it revealed an association with a sigmoidal trend between
888 estrogenic activity of extracts containing endogenous estrogens and breast cancer risk.

889 A perspective study was conducted by the same research group in order to evaluate the effect
890 of breast cancer treatment (chemotherapy and/or radiotherapy) and the influence of cancer
891 progression on the EDC biomarker (Fernández et al. 2017). The authors assessed the estrogenic
892 activity of adipose tissue in breast cancer patients at the diagnosis and during four other
893 consecutive periods (<6, 6-12, 12-18, >18 months) and found that estrogenic activity of both
894 types of extracts (containing xenoestrogens and containing endogenous estrogens -HPLC
895 fractionation technique) increased during the treatment with a maximum peak reached at 6-12
896 months, suggesting that cancer treatment might influence the levels of the EDC biomarker.

897 These studies demonstrated the association of the EDC biomarker with the risk and progression
898 of breast cancer in Spanish women. Nevertheless, the same results were not obtained in a
899 similar study performed on serum samples of Inuit women (Wielsøe et al. 2018). Indeed, in
900 this case-control study, the authors evaluated the estrogenic activity of two types of serum
901 extracts containing lipophilic xenoestrogens and containing PFAAs (HPLC fractionation
902 technique); the results showed that the estrogenic activity of both extracts was not associated
903 with breast cancer risk. This unexpected result can be due to the different assays used for the
904 assessment of estrogenic activity. Indeed, this study applied a gene reporter assay, while the
905 previous studies evaluated the estrogenic activity through the E-screen assay which is a
906 proliferation assay. Moreover, other differences might be responsible for the discrepancy
907 among the results, namely different characteristics among the studied populations, extraction
908 methods and exposure levels.

909 **6.4. Mother EDC exposure and child adverse health effects**

910 Since exposure to EDCs during pregnancy could represent a risk for children, some authors
911 applied the EDC biomarker in order to detect a possible association between the estrogenic
912 activity of placenta/serum extracts collected in mothers and adverse health effects in their
913 children.

914 To our knowledge, Fernández et al. (2007c) is the first study in which the EDC biomarker was
915 applied for this purpose. The aim of this study was to investigate the mother-child exposure to
916 organochlorine chemicals and its association with the risk of male urogenital malformations.
917 The estrogenic activity was evaluated on placenta samples collected from mothers whose
918 children were affected by cryptorchidism and/or hypospadias (n=46) and from controls. The
919 estrogenic activity of two types of extracts (containing endogenous estrogens and containing
920 xenoestrogens- HPLC fractionation technique), was not associated with the concentration of
921 16 organochlorine pesticides measured in the extracts. However, the estrogenic activity of

922 extracts containing xenoestrogens (EDC biomarker) showed a weak association with the risk
923 of malformation, which was stronger when adjusted for maternal age and birth weight. The
924 results of the study suggested that the EDC biomarker may be a risk factor for cryptorchidism
925 (Fernández et al. 2007b).

926 Other studies evaluated the effects on children of exposure to xenoestrogens during pregnancy.
927 In the study of Vilahur et al. (2013), the estrogenic activity of placenta extracts containing
928 xenoestrogens (HPLC fractionation technique) was positively associated with increased birth
929 weight and with a decrease in the risk of a rapid growth only in boys, although no association
930 was found between the EDC biomarker and body mass index measured at 14 months of age.
931 These results suggested that exposure to xenoestrogens during pregnancy may affect male child
932 health in particular. A sex difference was also observed in two subsequent studies of the same
933 authors (Vilahur et al. 2014a, Vilahur et al. 2014b). The first study showed an association
934 between increasing levels of estrogenic activity in extracts containing xenoestrogens (HPLC
935 fractionation technique) and lower AluYb8 DNA methylation, both measured in placentas of
936 male children, while no significant effect was detected analysing placentas of female children.
937 In the second study (Vilahur et al. 2014b), a lower average on motor development tests at 1-2
938 years of age was observed in boys with mothers having high estrogenic activity of placentas
939 (extracts containing xenoestrogens- HPLC fractionation technique), while no associations were
940 observed in girls. The association was not found in children at 4-5 years and neither in the
941 analysis of mental and cognitive tests in children at 1-2 years and 4-5 years.

942 Recently, Bjerregaard-Olesen et al. (2019) investigated the associations between exposure to
943 xenoestrogens during pregnancy (evaluated with the EDC biomarker) and child parameters (i.e.
944 birth weight, length and head circumference). Differently from the other studies, in this study
945 the biomarker was evaluated not in placenta extracts but in serum extracts and an extraction
946 optimized for PFAAs was used (HPLC fractionation technique and PFAA extraction). The

947 results showed that a higher estrogenic activity of serum extracts containing PFAAs was
948 associated with lower birth weight and length of children, suggesting that PFAA exposure
949 during pregnancy may affect child growth.

950 Finally, since EDC exposure during the first life period of children can occur through milk,
951 Sapbamrer et al. (2010) studied the relationship between maternal estrogenic activity of serum
952 and activity of breast milk (both treated in order to remove endogenous estrogens-DCC
953 technique) and the correlation between estrogenic activity and lipid levels. The results showed
954 a correlation between serum estrogenic activity and serum lipid levels, while no correlation
955 was found in milk. Moreover, the study demonstrated that the estrogenic activity in breast milk
956 was 8–13.5 times higher than in serum and that the two EDC biomarkers were not significantly
957 correlated, suggesting that child exposure through milk can not be precisely estimated
958 analysing maternal serum.

959

960 **7. Conclusion**

961 Estrogenic activity assays in human biological samples were applied for two main purposes:

- 962 i) as estrogen quantification and/or biomarker of estrogenic status;
- 963 ii) as a biomarker of exposure to EDCs.

964 Different methodologies were applied for the first purpose: some authors extracted biological
965 samples, while others tested them directly without any treatment. Several methodologies were
966 applied in order to obtain different levels of specificity: highly specific protocols with
967 extraction allowed the quantification of low concentrations of E2, while less specific protocols
968 without extraction, allowed the quantification of the total estrogenic activity.

969 Estrogenic activity as estrogen quantification and biomarker of estrogenic status was useful to
970 detect low concentrations of estrogens/estrogenic compounds and allowed the detection of
971 physiological variations of these compounds in prepubertal children and postmenopausal

972 women. This biomarker was also useful to study pediatric diseases characterized by hormonal
973 dysregulation and women hormone-dependent diseases. Overall, in many studies a high
974 estrogenic activity was associated with PP in females and sex differentiation disorders in males
975 and in some studies the use of this biomarker allowed the identification of EDC exposure as a
976 possible risk factor for these two diseases. Moreover, in girls the biomarker was also associated
977 with Turner syndrome (one study) and type 1 diabetes (one study), while in women a high
978 estrogenic activity was associated with higher breast cancer risk (three studies), lower hip
979 fracture risk (one study) and lower lung cancer survival (one study). These relationships should
980 be evaluated with caution since they were only demonstrated in a limited number of studies
981 and through the analysis of small groups of subjects. Furthermore, the results may have been
982 influenced by the type of estrogenic activity assay applied: some correlations were statistically
983 significant mainly using a type of estrogenic activity assay (e.g. ER α transcriptional activity
984 was correlated with breast cancer in all studies, while ER β was correlated only in one out of
985 three studies; ER β transcriptional activity was correlated with lower probability of lung cancer
986 survival, while ER α transcriptional activity was not). This biomarker was also important to
987 monitor estrogen suppression/enhancement in females and males treated with different drugs:
988 deslorelin, oral E2, transdermal E2, vaginal E2, letrozole, leuprolide acetate, anastrozole,
989 decoction of a Chinese medicinal plant.

990 For the second purpose, in order to use estrogenic activity assays as a EDC biomarker different
991 methodologies were applied on biological samples: some authors extracted biological samples,
992 while others tested them directly without any treatment; some authors divided endogenous
993 estrogens from xenoestrogens, while others tested samples without separation. The analysis of
994 these methodologies outlined some limitations. Regardless of the technique used for extraction
995 (solid phase extraction, liquid/liquid extraction or both) and separation (HPLC,
996 immunoprecipitation, DCC), the extraction collects different compounds with different

997 efficiencies depending on the protocol. Thus it may underestimate the effect of some
998 compounds, while the separation using HPLC is not always able to divide endogenous
999 hormones from xenoestrogens correctly.

1000 Since the EDC biomarker might be a useful tool to understand the relationship between
1001 exposure, biological effects and health risks associated with EDCs, it was used: (i) to study its
1002 relationship with exposure to EDCs, (ii) to investigate its relationship with adverse health
1003 effects, and (iii) to compare exposed populations with not exposed populations. The EDC
1004 biomarker showed different associations with exposure to different EDCs. This result can be
1005 explained considering that different EDCs may induce different estrogenic effects (agonistic
1006 or antagonistic effects), and that the EDC biomarker quantifies the cumulative effect induced
1007 by the combination of all these effects. Moreover, this result may also be due to different
1008 methodologies applied in different studies (extraction/no extraction and separation/no
1009 separation). Indeed, when samples were tested without separation the EDC biomarker also
1010 quantified the interaction between EDCs and endogenous hormones, while, when samples were
1011 tested after separation, this interaction was not measured. Conflicting results were also found
1012 analysing exposed populations (i.e. antagonistic effect measured in most of the Inuit
1013 populations, estrogenic activity measured in Faroese women), these results could be due to the
1014 use of different estrogenic activity assays (i.e. gene reporter assay in studies on Inuits, E-screen
1015 assay in the study on Faroese women). Finally, the EDC biomarker highlighted some possible
1016 associations between EDC exposure and diseases (i.e. breast cancer in Spanish women, child
1017 adverse health effects).

1018 In conclusion, the estrogenic activity on biological samples may have numerous applications
1019 and, depending on the methodology used, it can provide different information:

- 1020 i) It can be applied as a new method to quantify low levels of E2 in biological samples
1021 and for this purpose it should be applied extracting the biological sample;

1022 ii) It can be applied to evaluate the estrogenic status providing considerable insight into
1023 both physiological and pathological human conditions and for this purpose it should be
1024 applied without any treatment.

1025 iii) It can be applied to evaluate the presence of EDCs in biological samples and for this
1026 purpose it should be applied using a separation technique, which allows the separation
1027 of endogenous estrogens from xenoestrogens.

1028 iv) It can be applied to evaluate the presence of specific categories of EDCs (such as
1029 PFAAs) in biological samples and for this purpose the analytical techniques should be
1030 chosen according to the chemical characteristics of the EDCs investigated.

1031 v) It can be applied to assess the combined effect of endogenous estrogens and
1032 xenoestrogens in biological samples and for this purpose it should be applied without
1033 any separation technique.

1034 Therefore, the choice of methodology implies the evaluation of the research aim and the
1035 definition of the estrogenic activity as a biomarker of estrogenic status or EDC exposure.

1036 Studies using this kind of biomarker are still limited in number; however, considering its
1037 promising applications, future research is needed in this field in order to improve the
1038 standardization of the different methods.

1039

1040 **8. Funding**

1041 This research was supported by the Fondazione CRT (*Cassa di Risparmio di Torino*) a private,
1042 non-profit Italian organisation with full statutory and management autonomy (2018, 2nd round
1043 CRT Funding). Fondazione CRT projects and resources target various sectors: from the
1044 preservation and promotion of the artistic heritage and cultural activities to scientific
1045 research; from education and training to health care and assistance for vulnerable social groups;

1046 from civil protection and environmental safeguards to innovation in local institutions and
1047 support of economic development.

1048

1049 **9. Declaration of competing interest**

1050 The authors declare that they have no known competing financial interests or personal
1051 relationships that could have appeared to influence the work reported in this paper.

1052

1053 **10. References**

1054 Andersen H.R., Nielsen F., Nielsen J.B., Kjaerstad M.B., Baelum J., Grandjean P. (2007). Xeno-oestrogenic
1055 activity in serum as marker of occupational pesticide exposure. *Occupational and Environmental*
1056 *Medicine* 64(10): 708-714.

1057 Arrebola J.P., Fernández M.F., Molina-Molina J.M., Martin-Olmedo P., Exposito J., Olea, N. (2012). Predictors
1058 of the total effective xenoestrogen burden (TEXB) in human adipose tissue. A pilot study. *Reproductive*
1059 *Toxicology* 33(1): 45-52.

1060 Arrebola J.P., Pumarega J., Gasull M., Fernández M.F., Martin-Olmedo P., Molina-Molina J.M., Fernandez-
1061 Rodriguez M., Porta M., Olea, N. (2013). Adipose tissue concentrations of persistent organic pollutants and
1062 prevalence of type 2 diabetes in adults from Southern Spain. *Environmental Research* 122: 31-37.

1063 Bellem A., Meiyappan S., Romans S., Einstein G. (2011). Measuring estrogens and progestagens in humans: an
1064 overview of methods. *Gender Medicine* 8(5): 283-299.

1065 Benagiano M., Bianchi P., D’Elios M. M., Brosens I., Benagiano G. (2019). Autoimmune diseases: role of steroid
1066 hormones. *Best Practice & Research Clinical Obstetrics & Gynaecology* 60: 24 – 34.

1067 Bergman A., Heindel J.J., Kasten T., Kidd K.A., S. Jobling, Neira M., Zoeller R.T., Becher G., Bjerregaard P.,
1068 Bornman R., Brandt I., Kortenkamp A., Muir D., Drisse M.B., Ochieng R., Skakkebaek N.E., Byléhn A.S., Iguchi
1069 T., Toppari J., Woodruff T.J. (2013). The impact of endocrine disruption: a consensus statement on the state of
1070 the science. *Environmental Health Perspectives* 121(4): a104 – a106.

1071 Bicchi C., Schilirò T., Pignata C., Fea E., Cordero C., Canale F., Gilli G. (2009). Analysis of environmental
1072 endocrine disrupting chemicals using the E-screen method and stir bar sorptive extraction in wastewater treatment
1073 plant effluents. *Science of the Total Environment* 407(6):1842-51.

1074 Bjerregaard-Olesen C., Bach C.C., Long M., Wielsøe M., Bech B.H., Henriksen T. B., Olsen J., Bonefeld-
1075 Jørgensen E.C. (2019). Associations of fetal growth outcomes with measures of the combined xenoestrogenic
1076 activity of maternal serum perfluorinated alkyl acids in Danish pregnant women. *Environmental Health*
1077 *Perspectives* 127(01): 017006.

1078 Bjerregaard-Olesen C., Bossi R., Bech B.H., Bonefeld-Jørgensen E.C. (2015). Extraction of perfluorinated alkyl
1079 acids from human serum for determination of the combined xenoestrogenic transactivity: A method
1080 development. *Chemosphere* 129: 232-238.

1081 Bjerregaard-Olesen C., Ghisari M., Bonefeld-Jørgensen E.C. (2016). Activation of the estrogen receptor by human
1082 serum extracts containing mixtures of perfluorinated alkyl acids from pregnant women. *Environmental*
1083 *Research* 151: 71-79.

1084 Bonefeld-Jørgensen E.C. (2010). Biomonitoring in Greenland: human biomarkers of exposure and effects-a short
1085 review. *Rural and Remote Health*. 10(2):1362

1086 Bonefeld-Jørgensen E.C., Ghisari M., Wielsøe M., Bjerregaard-Olesen C., Kjeldsen L.S., Long M. (2014).
1087 Biomonitoring and hormone-disrupting effect biomarkers of persistent organic pollutants in vitro and ex vivo.
1088 *Basic & Clinical Pharmacology & Toxicology* 115(1): 118-128.

1089 Bonefeld-Jørgensen E.C., Grünfeld H.T., Gjermandsen I.M. (2005). Effect of pesticides on estrogen receptor
1090 transactivation in vitro: a comparison of stable transfected MVLN and transient transfected MCF-7 cells.
1091 *Molecular and Cellular Endocrinology* 244(1-2): 20-30.

1092 Bonefeld-Jørgensen E.C., Hjelmberg P.S., Reinert T.S., Andersen B.S., Lesovoy V., Lindh C.H., Hagmar L.,
1093 Giwercman A., Erlandsen M., Manicardi G., Spanò, M., Toft G. and Bonde J.P. (2006). Xenoestrogenic activity
1094 in blood of European and Inuit populations. *Environmental Health* 5(1): 12.

1095 Brouwers M.M., Besselink H., Bretveld R.W., Anzion R., Scheepers P.T., Brouwer A., Roeleveld N. (2011).
1096 Estrogenic and androgenic activities in total plasma measured with reporter-gene bioassays: relevant exposure
1097 measures for endocrine disruptors in epidemiologic studies? *Environment International* 37(3): 557-564.

1098 Calsolaro V., Pasqualetti G., Niccolai F., Caraccio N., Monzani F. (2017). Thyroid disrupting chemicals.
1099 *International Journal of Molecular Sciences* 18(12): 2583.

1100 Chamas A., Pham H.T.M., Jähne M., Hettwer K., Uhlig S., Simon K., Einspanier A., Baronian K., Kunze G.
1101 (2017). Simultaneous detection of three sex steroid hormone classes using a novel yeast-based biosensor.
1102 *Biotechnology and Bioengineering* 114(7): 1539-1549.

1103 Damstra T., Barlow S., Bergman A., Kavlock R., Van Der Kraak G. (2002). Global assessment of the state-of-
1104 the-science of endocrine disruptors. Geneva: World Health Organization, 11-32.

1105 Demeneix B., Slama R. (2019). Endocrine disruptors: from scientific evidence to human health protection.
1106 European Parliament Reports.

1107 Diamanti-Kandarakis E., Bourguignon J.P., Giudice L.C., Hauser R., Prins G.S., Soto A.M., Zoeller R.T., Gore
1108 A.C. (2009). Endocrine-disrupting chemicals: an Endocrine Society scientific statement. *Endocrine Reviews*
1109 30(4): 293-342.

1110 Dziewirska E., Hanke W., Jurewicz J. (2018). Environmental non-persistent endocrine-disrupting chemicals
1111 exposure and reproductive hormones levels in adult men. *International Journal of Occupational Medicine and*
1112 *Environmental Health* 31(5):551 – 573.

1113 Escher B.I., Aït-Aïssa S., Behnisch P.A., Brack W., Brion F., Brouwer A., Buchinger S., Crawford S.E., Du
1114 Pasquier D., Hamers T., Hettwer K., Hilscherová K., Hollert H., Kase R., Kienle C., Tindall A.J., Tuerk J., van
1115 der Oost R., Vermeirssen E., Neale P.A. (2018). Effect-based trigger values for in vitro and in vivo bioassays
1116 performed on surface water extracts supporting the environmental quality standards (EQS) of the European Water
1117 Framework Directive. *Science of The Total Environment* 628: 748-765.

1118 Fejerman L., Sanchez S.S., Thomas R., Tachachartvanich P., Riby J., Gomez S.L., John E.M., Smith M.T. (2016).
1119 Association of lifestyle and demographic factors with estrogenic and glucocorticogenic activity in Mexican
1120 American women. *Carcinogenesis* 37(9): 904-911.

1121 Fernández M.F., Aguilar-Garduno C., Molina-Molina J.M., Arrebola J.P., Olea, N. (2008). The total effective
1122 xenoestrogen burden, a biomarker of exposure to xenoestrogen mixtures, is predicted by the (anti) estrogenicity
1123 of its components. *Reproductive Toxicology* 26(1): 8-12.

1124 Fernández M.F., Molina-Molina J.M., Lopez-Espinosa M.J., Freire C., Campoy C., Ibarluzea J., Torne P., Pedraza
1125 V., Olea N. (2007b). Biomonitoring of environmental estrogens in human tissues. *International Journal of*
1126 *Hygiene and Environmental Health* 210(3-4): 429-432.

1127 Fernández M.F., Olmos B., Granada A., López-Espinosa M.J., Molina-Molina J.M., Fernandez J.M., Cruz M.,
1128 Olea-Serrano F., Olea N. (2007c). Human exposure to endocrine-disrupting chemicals and prenatal risk factors
1129 for cryptorchidism and hypospadias: a nested case–control study. *Environmental Health Perspectives* 115 (Suppl
1130 1): 8-14.

1131 Fernández M.F., Pumarega J., Porta M., Molina-Molina J.M., Arrebola J.P., Olea N. (2017). Changes in the total
1132 effective xenoestrogen burden (TEXB) of breast cancer patients during an 18-month post-surgical follow-
1133 up. *Reproductive Toxicology* 69: 212-220.

1134 Fernández M.F., Rivas A., Olea-Serrano F., Cerrillo I., Molina-Molina J.M., Araque P., Martinez-Vidal J.L., Olea
1135 N. (2004). Assessment of total effective xenoestrogen burden in adipose tissue and identification of chemicals
1136 responsible for the combined estrogenic effect. *Analytical and Bioanalytical Chemistry* 379(1): 163-170.

1137 Fernández M.F., Santa-Marina L., Ibarluzea J.M., Exposito J., Aurrekoetxea J.J., Torne P., Laguna J., Rueda A.I.,
1138 Pedraza V., Olea N. (2007a). Analysis of population characteristics related to the total effective xenoestrogen
1139 burden: a biomarker of xenoestrogen exposure in breast cancer. *European Journal of Cancer* 43(8): 1290-1299.

1140 Fourkala E.O., Zaikin A., Burnell M., Gentry-Maharaj A., Ford J., Gunu R., Soromani C., Hasenbrink G., Jacobs
1141 I., Dawnay A., Widschwendter M., Lichtenberg-Frate H., Menon U. (2012). Association of serum sex steroid
1142 receptor bioactivity and sex steroid hormones with breast cancer risk in postmenopausal women. *Endocrine-
1143 Related Cancer* 19(2): 137-147.

1144 Freire C., Ramos R., Amaya E., Fernández M.F., Santiago-Fernández P., Lopez-Espinosa M.J., Arrebola J.P.,
1145 Olea N. (2010). Newborn TSH concentration and its association with cognitive development in healthy
1146 boys. *European Journal of Endocrinology* 163(6): 901-909.

1147 Gaspari L., Paris F., Jeandel C., Sultan C. (2011b). Peripheral precocious puberty in a 4-month-old girl: role of
1148 pesticides? *Gynecological Endocrinology* 27(9): 721-724.

1149 Gaspari L., Paris F., Philibert P., Audran F., Orsini M., Servant N., Maimoun L., Kalfa N., Sultan C. (2011a).
1150 Idiopathic partial androgen insensitivity syndrome in 28 newborn and infant males: impact of prenatal exposure
1151 to environmental endocrine disruptor chemicals? *European Journal of Endocrinology* 165(4): 579.

1152 Hampl R., Kubátová J., Stárka L. (2016). Steroids and endocrine disruptors—History, recent state of art and open
1153 questions. *The Journal of Steroid Biochemistry and Molecular Biology* 155: 217-223.

1154 Hasenbrink G., Sievernich A., Wildt L., Ludwig J., Lichtenberg-Fraté H. (2006). Estrogenic effects of natural and
1155 synthetic compounds including tibolone assessed in *Saccharomyces cerevisiae* expressing the human estrogen α
1156 and β receptors. *The FASEB journal*, 20(9): 1552-1554.

1157 Hettwer K., Jähne M., Frost K., Giersberg M., Kunze G., Trimborn M., Reif M., Türk J., Gehrmann L., Dardenne
1158 F., De Croock F., Abraham M., Schoop A., Waniek J.J., Bucher T., Simon E., Vermeirssen E., Werner A., Hellauer
1159 K., Wallentits U., Drewes J.E., Dietzmann D., Routledge E., Beresford N., Zietek T., Siebler M., Simon A., Bielak
1160 H., Hollert H., Müller Y., Harff M., Schiwy S., Simon K., Uhlig S. (2018). Validation of *Arxula* Yeast Estrogen

1161 Screen assay for detection of estrogenic activity in water samples: results of an international interlaboratory study.
1162 Science of The Total Environment 621: 612-625.

1163 Hjelmberg P.S., Ghisari M., Bonefeld-Jørgensen E.C. (2006). SPE-HPLC purification of endocrine-disrupting
1164 compounds from human serum for assessment of xenoestrogenic activity. Analytical and Bioanalytical
1165 Chemistry 385(5): 875-887.

1166 Ibarluzea J.M., Fernández M.F., Santa-Marina L., Olea-Serrano M.F., Rivas A.M., Aurrekoetxea J.J., Expósito J.,
1167 Lorenzo M., Tornè P., Villalobos M., Pedraza V., Sasco A.J., Olea N. (2004). Breast cancer risk and the combined
1168 effect of environmental estrogens. Cancer Causes & Control 15(6): 591-600.

1169 ISO 19040-1 (2018). Water quality — Determination of the estrogenic potential of water and waste water — Part
1170 1: Yeast estrogen screen (*Saccharomyces cerevisiae*).

1171 ISO 19040-2 (2018). Water quality — Determination of the estrogenic potential of water and waste water — Part
1172 2: Yeast estrogen screen (A-YES, *Arxula adenivorans*).

1173 ISO 19040-3 (2018). Water quality — Determination of the estrogenic potential of water and waste water — Part
1174 3: In vitro human cell-based reporter gene assay.

1175 Janfaza M., Sherman T.I., Larmore K.A., Brown-Dawson J., Klein K.O. (2006). Estradiol levels and secretory
1176 dynamics in normal girls and boys as determined by an ultrasensitive bioassay: a 10 year experience. Journal of
1177 Pediatric Endocrinology and Metabolism 19(7): 901-910.

1178 Jarošová B., Erseková A., Hilscherová K., Loos R., Gawlik B.M., Giesy J.P., Bláha L. (2014). Europe-wide survey
1179 of estrogenicity in wastewater treatment plant effluents: the need for the effect-based monitoring. Environmental
1180 Science and Pollution Research 21(18): 10970-10982.

1181 Kabir E.R., Rahman M.S., Rahman I. (2015). A review on endocrine disruptors and their possible impacts on
1182 human health. Environmental Toxicology and Pharmacology 40(1): 241–258.

1183 Kanaya N., Nguyen D.M., Lu H., Wang Y.Z., Hsin L.Y., Petreas M., Nelson D., Guo W., Reynold P., Synold T.,
1184 Chen S. (2015). AroER tri-screen™ is a novel functional assay to estimate both estrogenic and estrogen precursor
1185 activity of chemicals or biological specimens. Breast Cancer Research and Treatment 151(2): 335-345.

1186 Kanno Y., Okada H., Kobayashi T., Takenaka T., Suzuki H. (2007). Effects of endocrine disrupting substance on
1187 estrogen receptor gene transcription in dialysis patients. Therapeutic Apheresis and Dialysis 11(4): 262-265.

1188 Karwacka A., Zamkowska D., Radwan M., Jurewicz, J. (2019). Exposure to modern, widespread environmental
1189 endocrine disrupting chemicals and their effect on the reproductive potential of women: an overview of current
1190 epidemiological evidence. Human Fertility 22(1): 2-25.

1191 Kase R., Javurkova B., Simon E., Swart K., Buchinger S., Könemann S., Escher B.I., Carere M., Dulio V., Ait-
1192 Aïssa S., Hollert H., Valsecchi S., Polesello S., Behnisch P., Di Paolo C., Olbrich D., Sychrova E., Gundlach M.,
1193 Schlichting R., Leborgne L., Clara M., Scheffknecht C., Marneffe Y., Chalón C., Tusil P., Soldan P., von Danwitz
1194 B., Schwaiger J., Moran Palao A., Bersani F., Perceval O., Kienle C., Vermeirssen E., Hilscherova K.,
1195 Reifferscheid G., Werner I. (2018). Screening and risk management solutions for steroidal estrogens in surface
1196 and wastewater. *TrAC Trends in Analytical Chemistry* 102: 343-358.

1197 Kiyama R., Wada-Kiyama Y. (2015). Estrogenic endocrine disruptors: Molecular mechanisms of action.
1198 *Environment International* 83: 11-40.

1199 Klein K.O., Baron J., Barnes K.M., Pescovitz O.H., Cutler G.B. (1998a). Use of an ultrasensitive recombinant
1200 cell bioassay to determine estrogen levels in girls with precocious puberty treated with a luteinizing hormone-
1201 releasing hormone agonist. *The Journal of Clinical Endocrinology & Metabolism* 83(7): 2387-2389.

1202 Klein K.O., Baron J., Colli M.J., McDonnell D.P., Cutler G.B. (1994). Estrogen levels in childhood determined
1203 by an ultrasensitive recombinant cell bioassay. *The Journal of Clinical Investigation* 94(6): 2475-2480.

1204 Klein K.O., Demers L.M., Santner S.J., Baron J., Cutler G.B., Santen R.J. (1995). Use of ultrasensitive
1205 recombinant cell bioassay to measure estrogen levels in women with breast cancer receiving the aromatase
1206 inhibitor, letrozole. *The Journal of Clinical Endocrinology & Metabolism* 80(9): 2658-2660.

1207 Klein K.O., Larmore K.A., De Lancey E., Brown J.M., Considine R.V., Hassink S.G. (1998b). Effect of obesity
1208 on estradiol level, and its relationship to leptin, bone maturation, and bone mineral density in children. *The Journal*
1209 *of Clinical Endocrinology & Metabolism* 83(10): 3469-3475.

1210 Klein K.O., Martha P.M., Blizzard R.M., Herbst T., Rogol A.D. (1996). A longitudinal assessment of hormonal
1211 and physical alterations during normal puberty in boys. II. Estrogen levels as determined by an ultrasensitive
1212 bioassay. *The Journal of Clinical Endocrinology & Metabolism* 81(9): 3203-3207.

1213 Klein K.O., Méricq V., Brown-Dawson J.M., Larmore K.A., Cabezas P., Cortinez A. (1999). Estrogen levels in
1214 girls with premature thelarche compared with normal prepubertal girls as determined by an ultrasensitive
1215 recombinant cell bioassay. *The Journal of Pediatrics* 134(2): 190-192.

1216 Könemann S., Kase R., Simon E., Swart K., Buchinger S., Schlüsener M., Hollert H., Escher B.I., Werner I., Ait-
1217 Aïssa S., Vermeirssen E., Dulio V., Valsecchi S., Polesello S., Behnisch P., Javurkova B., Perceval O., Di Paolo
1218 C., Olbrich D., Sychrova E., Schlichting R., Leborgne L., Clara M., Scheffknecht C., Marneffe Y., Chalón C.,
1219 Tušil P., Soldan P., von Danwitz B., Schwaiger J., San Martín Becares M.I., Bersani F., Hilscherová K.,

1220 Reifferscheid G., Ternes T., Carere M. (2018). Effect-based and chemical analytical methods to monitor estrogens
1221 under the European Water Framework Directive. *Trends in Analytical Chemistry* 102: 225-235.

1222 Krüger T., Ghisari M., Hjelmberg P.S., Deutch B., Bonefeld-Jørgensen E.C. (2008a). Xenohormone
1223 transactivities are inversely associated to serum POPs in Inuit. *Environmental Health* 7(1): 38.

1224 Krüger T., Long M., Ghisari M., Bonefeld-Jørgensen E. C. (2012). The combined effect of persistent organic
1225 pollutants in the serum POP mixture in Greenlandic Inuit: xenoestrogenic, xenoandrogenic and dioxin-like
1226 transactivities. *Biomarkers* 17(8): 692-705.

1227 Krüger T., Spano M., Long M., Eleuteri P., Rescia M., Hjelmberg P.S., Manicardi G., Bizzaro D., Giwercman A.,
1228 Toft G., Bonde J.P., Bonefeld-Jørgensen E.C. (2008b). Xenobiotic activity in serum and sperm chromatin integrity
1229 in European and inuit populations. *Molecular Reproduction and Development: Incorporating Gamete*
1230 *Research* 75(4): 669-680.

1231 Larmore K.A., Klein K.O. (2000). Estradiol suppression and recovery during leuprolide acetate treatment in
1232 women as determined weekly by an ultrasensitive recombinant cell bioassay. *Gynecological Endocrinology* 14(6):
1233 405-410.

1234 Larmore K.A., O' Connor D., Sherman T.I., Funanage V.L., Hassink S.G., Klein K.O. (2002). Leptin and estradiol
1235 as related to change in pubertal status and body weight. *Medical Science Monitor* 8(3): CR206-CR210.

1236 Legler J., van den Brink C.E., Brouwer A., Murk A. J., van der Saag P.T., Vethaak A.D., van der Burg B. (1999).
1237 Development of a stably transfected estrogen receptor-mediated luciferase reporter gene assay in the human T47D
1238 breast cancer cell line. *Toxicological sciences: an official journal of the Society of Toxicology* 48(1): 55-66.

1239 Leusch F.D., De Jager C., Levi Y., Lim R., Puijker L., Sacher F., Tremblay L.A., Wilson V.S., Chapman H. F.
1240 (2010). Comparison of five in vitro bioassays to measure estrogenic activity in environmental waters.
1241 *Environmental Science & Technology* 44(10): 3853-3860.

1242 Li J., Lee L., Gong Y., Shen P., Wong S.P., Wise S.D., Yong E.L. (2009). Bioassays for estrogenic activity:
1243 Development and validation of estrogen receptor (ER α /ER β) and breast cancer proliferation bioassays to measure
1244 serum estrogenic activity in clinical studies. *Assay and Drug Development Technologies* 7(1): 80-89.

1245 Lim V.W., Li J., Gong Y., Jin A., Yuan J.M., Yong E.L., Koh W.P. (2014a). Serum estrogen receptor bioactivity
1246 and breast cancer risk among postmenopausal women. *Endocrine-Related Cancer* 21(2): 263-273.

1247 Lim V.W., Li J., Gong Y., Yuan J.M., Wu T.S., Hammond G.L., Jin A., Koh W., Yong E.L. (2012). Serum free
1248 estradiol and estrogen receptor- α mediated activity are related to decreased incident hip fractures in older women.
1249 *Bone* 50(6): 1311-1316.

1250 Lim V.W., Lim W.Y., Zhang Z., Li J., Gong Y., Seow A., Yong E.L. (2014b). Serum estrogen receptor beta
1251 mediated bioactivity correlates with poor outcome in lung cancer patients. *Lung Cancer* 85(2): 293-298.

1252 Long M., Stronati A., Bizzaro D., Krüger T., Manicardi G.C., Hjelmberg P.S., Spanò M., Giwercman A., Toft G.,
1253 Bonde J.P., Bonefeld-Jørgensen E.C. (2007). Relation between serum xenobiotic-induced receptor activities and
1254 sperm DNA damage and sperm apoptotic markers in European and Inuit populations. *Reproduction* 133(2): 517-
1255 530.

1256 Lopez-Espinosa M.J., Silva E., Granada A., Molina-Molina J.M., Fernández M.F., Aguilar-Garduño C., Olea-
1257 Serrano F., Kortenkamp A., Olea N. (2009). Assessment of the total effective xenoestrogen burden in extracts of
1258 human placentas. *Biomarkers* 14(5): 271-277.

1259 Martínez D., Castro A., Merino P.M., López P., Lardone M.C., Iñiguez G., Cassorla F., Codner E. (2016).
1260 Oestrogen activity of the serum in adolescents with Type 1 diabetes. *Diabetic Medicine* 33(10): 1366-1373.

1261 Mauras N., O'Brien K.O., Klein K.O., Hayes V. (2000). Estrogen suppression in males: metabolic effects. *The*
1262 *Journal of Clinical Endocrinology & Metabolism* 85(7): 2370-2377.

1263 Mauras N., Welch S., Rini A., Klein K.O. (2004). An open label 12-month pilot trial on the effects of the aromatase
1264 inhibitor anastrozole in growth hormone (GH)-treated GH deficient adolescent boys. *Journal of Pediatric*
1265 *Endocrinology and Metabolism* 17(12): 1597-1606.

1266 Medina M.B., Sherman J.T. (1986). High performance liquid chromatographic separation of anabolic oestrogens
1267 and ultraviolet detection of 17 β -oestradiol, zeranol, diethylstilboestrol or zearalenone in avian muscle tissue
1268 extracts. *Food Additives & Contaminants* 3(3): 263-272.

1269 Merrheim J., Villegas J., Van Wassenhove J., Khansa R., Berrih-Aknin S., le Panse R., Dragin N. (2020).
1270 Estrogen, estrogen-like molecules and autoimmune diseases. *Autoimmunity Reviews* 19: 102468.

1271 Mesa Valencia D.C., Mericq V., Corvalán C., Pereira A. (2019). Obesity and Related Metabolic Biomarkers and
1272 Its Association with Serum Levels of Estrogen in Pre-pubertal Chilean Girls. *Endocrine research* 1-9.

1273 Mueller S.O. (2004). Xenoestrogens: mechanisms of action and detection methods. *Analytical and Bioanalytical*
1274 *Chemistry* 378(3): 582-587.

1275 Natarajan K., Overstreet J.W., Rogers J.M., Denison M.S., Chen J., Lohstroh P.N., McConnell D.S., Lasley B.L.
1276 (2002). Detection of xenoestrogens in serum after immunoprecipitation of endogenous steroidal
1277 estrogens. *Environmental Health Perspectives* 110(8): 791-795.

1278 OECD (2015). Test N° 493: Performance-Based Test Guideline for Human Recombinant Estrogen Receptor
1279 (hrER) In Vitro Assays to Detect Chemicals with ER Binding Affinity, OECD Guidelines for the Testing of
1280 Chemicals, Section 4, OECD Publishing, Paris, <https://doi.org/10.1787/9789264242623-en>.

1281 OECD (2016). Test N° 455: Performance-Based Test Guideline for Stably Transfected Transactivation In Vitro
1282 Assays to Detect Estrogen Receptor Agonists and Antagonists, OECD Guidelines for the Testing of Chemicals,
1283 Section 4, OECD Publishing, Paris, <https://doi.org/10.1787/9789264265295-en>.

1284 OECD (2018). Revised Guidance Document 150 on Standardised Test Guidelines for Evaluating Chemicals for
1285 Endocrine Disruption, OECD Series on Testing and Assessment, OECD Publishing, Paris.
1286 <https://doi.org/10.1787/9789264304741-en>.

1287 Pamplona-Silva M.T., Mazzeo D.E.C., Bianchi J., Marin-Morales M.A. (2018). Estrogenic compounds: chemical
1288 characteristics, detection methods, biological and environmental effects. *Water, Air, & Soil Pollution* 229(5): 144.

1289 Paris F., Gaspari L., Servant N., Philibert P., Sultan C. (2013). Increased serum estrogenic bioactivity in girls with
1290 premature thelarche: a marker of environmental pollutant exposure? *Gynecological Endocrinology* 29(8): 788-
1291 792.

1292 Paris F., Jeandel C., Servant N., Sultan C. (2006). Increased serum estrogenic bioactivity in three male newborns
1293 with ambiguous genitalia: a potential consequence of prenatal exposure to environmental endocrine disruptors.
1294 *Environmental Research* 100(1): 39-43.

1295 Paris F., Servant N., Térouanne B., Balaguer P., Nicolas J.C., Sultan C. (2002). A new recombinant cell bioassay
1296 for ultrasensitive determination of serum estrogenic bioactivity in children. *The Journal of Clinical Endocrinology*
1297 *& Metabolism* 87(2): 791-797.

1298 Pastor-Barriuso R., Fernández M.F., Castaño-Vinyals G., Whelan D., Pérez-Gómez B., Llorca J., Villanueva C.
1299 M., Guevara M., Molina-Molina J., Artacho-Cordón F., Barriuso-Lapresa L., Tusquets I., Dierssen-Sotos T.,
1300 Aragonés N., Olea N., Kogevinas M., Pollán M. (2016). Total effective xenoestrogen burden in serum samples
1301 and risk for breast cancer in a population-based multicase–control study in Spain. *Environmental Health*
1302 *Perspectives* 124(10): 1575-1582.

1303 Pedersen M., Halldorsson T.I., Mathiesen L., Mose T., Brouwer A., Hedegaard M., Loft S., Kleinjans J.C.S.,
1304 Besselink H., Knudsen L.E., Knudsen L.E. (2010). Dioxin-like exposures and effects on estrogenic and
1305 androgenic exposures and micronuclei frequency in mother–newborn pairs. *Environment International* 36(4):
1306 344-351.

1307 Pereira A., Corvalán C., Uauy R., Klein K.O., Mericq V. (2015). Ultrasensitive estrogen levels at 7 years of age
1308 predict earlier thelarche: evidence from girls of the growth and obesity Chilean cohort. *European Journal of*
1309 *Endocrinology* 173(6): 835-842.

1310 Plíšková M., Vondráček J., Canton R.F., Nera J., Kočan A., Petřík J., Trnovec T., Sanderson T., van den Berg M.,
1311 Machala M. (2005). Impact of polychlorinated biphenyls contamination on estrogenic activity in human male
1312 serum. *Environmental Health Perspectives* 113(10): 1277-1284.

1313 Pons M., Gagne D., Nicolas J.C., Mehtali M. (1990). A new cellular model of response to estrogens: a
1314 bioluminescent test to characterize (anti) estrogen molecules. *Biotechniques* 9(4): 450-459.

1315 Rasmussen T.H., Nielsen F., Andersen H.R., Nielsen J.B., Weihe P., Grandjean, P. (2003). Assessment of
1316 xenoestrogenic exposure by a biomarker approach: application of the E-Screen bioassay to determine estrogenic
1317 response of serum extracts. *Environmental Health* 2(1): 12.

1318 Rasmussen T.H., Nielsen J.B. (2002). Critical parameters in the MCF-7 cell proliferation bioassay (E-Screen).
1319 *Biomarkers* 7(4): 322-336.

1320 Rivas A., Fernández M.F., Cerrillo I., Ibarluzea J., Olea-Serrano M.F., Pedraza V., Olea N. (2001). Human
1321 exposure to endocrine disrupters: standardisation of a marker of estrogenic exposure in adipose
1322 tissue. *Apmis* 109(S103): S189-S202.

1323 Rivas A., Olea N. (1997). Human exposure to endocrine-disrupting chemicals: assessing the total estrogenic
1324 xenobiotic burden. *TrAC Trends in Analytical Chemistry* 16(10): 613-619.

1325 Rogers J.M., Denison M.S. (2000). Recombinant cell bioassays for endocrine disruptors: development of a stably
1326 transfected human ovarian cell line for the detection of estrogenic and anti-estrogenic chemicals. *In vitro &*
1327 *molecular toxicology* 13(1): 67-82.

1328 Routledge E.J., Sumpter J.P. (1996). Estrogenic activity of surfactants and some of their degradation products
1329 assessed using a recombinant yeast screen. *Environmental Toxicology and Chemistry: An International Journal*
1330 15(3): 241-248.

1331 Rosner W., Hankinson S.E., Sluss P.M., Vesper H.W., Wierman M.E. (2013). Challenges to the measurement of
1332 estradiol: an endocrine society position statement. *The Journal of Clinical Endocrinology & Metabolism* 98(4):
1333 1376-1387.

1334 Sanchez S.S., Tachachartvanich P., Stanczyk F.Z., Gomez S.L., John E.M., Smith M.T., Fejerman L. (2019).
1335 Estrogenic activity, race/ethnicity, and Indigenous American ancestry among San Francisco Bay Area women.
1336 *PloS one* 14(3): e0213809.

1337 Santen R.J., Lee J.S., Wang S., Demers L.M., Mauras N., Wang H., Singh R. (2008). Potential role of ultra-
1338 sensitive estradiol assays in estimating the risk of breast cancer and fractures. *Steroids* 73(13): 1318-1321.

1339 Santen R.J., Pinkerton J.V., Conaway M., Ropka M., Wisniewski L., Demers L., Klein K. O. (2002). Treatment
1340 of urogenital atrophy with low-dose estradiol: preliminary results. *Menopause* 9(3): 179-187.

1341 Sapbamrer R., Prapamontol T., Hock B. (2010). Assessment of estrogenic activity and total lipids in maternal
1342 biological samples (serum and breast milk). *Ecotoxicology and Environmental Safety* 73(4): 679-684.

1343 Seifert M., Haindl S., Hock B. (1999). Development of an enzyme linked receptor assay (ELRA) for estrogens
1344 and xenoestrogens. *Analytica Chimica Acta* 386(3): 191-199.

1345 Séronie-Vivien S., Dalenc F., Balaguer P., Nicolas J.C., Roché H., Faye J.C. (2004). A recombinant cell bioassay
1346 for measurement of overall estrogenic activity of serum: preliminary results in women with breast cancer. *Clinical*
1347 *Chemistry and Laboratory Medicine* 42(8): 889-895.

1348 Sonnenschein C., Soto A.M., Fernández M.F., Olea N., Olea-Serrano M.F., Ruiz-Lopez M.D. (1995).
1349 Development of a marker of estrogenic exposure in human serum. *Clinical Chemistry* 41(12): 1888-1895.

1350 Sonneveld E., Jansen H.J., Riteco J.A., Brouwer A., van der Burg B. (2005). Development of androgen-and
1351 estrogen-responsive bioassays, members of a panel of human cell line-based highly selective steroid-responsive
1352 bioassays. *Toxicological Sciences* 83(1): 136-148.

1353 Soto A. M., Fernández M.F., Luizzi M.F., Oles Karasko A.S., Sonnenschein C. (1997). Developing a marker of
1354 exposure to xenoestrogen mixtures in human serum. *Environmental health perspectives* 105(suppl 3): 647-654.

1355 Soto A.M., Maffini M.V., Schaeberle C.M., Sonnenschein C. (2006). Strengths and weaknesses of in vitro assays
1356 for estrogenic and androgenic activity. *Best Practice & Research Clinical Endocrinology & Metabolism* 20(1):
1357 15-33.

1358 Sultan C., Gaspari L., Maimoun L., Kalfa N., Paris F. (2018). Disorders of puberty. *Best Practice & Research*
1359 *Clinical Obstetrics & Gynaecology* 48, 62-89.

1360 Taboada M., Santen R., Lima J., Hossain J., Singh R., Klein K.O., Mauras N. (2011). Pharmacokinetics and
1361 pharmacodynamics of oral and transdermal 17 β estradiol in girls with Turner syndrome. *The Journal of Clinical*
1362 *Endocrinology & Metabolism* 96(11): 3502-3510.

1363 Toft G., Long M., Krüger T., Hjelmberg P.S., Bonde J.P., Rignell-Hydbom A., Tyrkiel E., Hagmar L., Giwercman
1364 A., Spanó M., Bizzaro D., Pedersen H.S., Lesovoy V., Ludwicki J.K., Bonefeld-Jørgensen E.C. (2007). Semen
1365 quality in relation to xenohormone and dioxin-like serum activity among Inuits and three European
1366 populations. *Environmental Health Perspectives* 115(Suppl 1): 15-20.

1367 Torres-Santiago L., Mericq V., Taboada M., Unanue N., Klein K.O., Singh R., Hossain J., Santen R.J., Ross J.L.,
1368 Mauras N. (2013). Metabolic effects of oral versus transdermal 17 β -estradiol (E2): a randomized clinical trial in
1369 girls with Turner syndrome. *The Journal of Clinical Endocrinology & Metabolism* 98(7): 2716-2724.

1370 Vilahur N., Bustamante M., Byun H.M., Fernández M.F., Santa Marina L., Basterrechea M., Ballester F., Murcia
1371 M., Tardón A., Fernández-Somoano A., Estivill X., Olea N., Sunyer J., Baccarelli A.A. (2014a). Prenatal
1372 exposure to mixtures of xenoestrogens and repetitive element DNA methylation changes in human
1373 placenta. *Environment International* 71: 81-87.

1374 Vilahur N., Fernández M.F., Bustamante M., Ramos R., Forns J., Ballester F., Murcia M., Riaño I., Ibarluzea J.,
1375 Olea N., Sunyer J. (2014b). In utero exposure to mixtures of xenoestrogens and child neuropsychological
1376 development. *Environmental Research* 134: 98-104.

1377 Vilahur N., Molina-Molina J.M., Bustamante M., Murcia M., Arrebola J.P., Ballester F., Mendez M.A., Garcia-
1378 Esteban R., Guxens M., Santa Marina L., Tardón A., Sunyer J., Olea N., Fernandez M.F. (2013). Male specific
1379 association between xenoestrogen levels in placenta and birthweight. *Environment International* 51: 174-181.

1380 Villalobos M., Olea N., Brotons J.A., Olea-Serrano M.F., Ruiz de Almodovar J.M., Pedraza V. (1995). The E-
1381 screen assay: a comparison of different MCF7 cell stocks. *Environmental Health Perspectives* 103(9): 844-850.

1382 Wagner M., Kienle C., Vermeirssen E.L., Oehlmann J. (2017). Endocrine disruption and in vitro ecotoxicology:
1383 Recent advances and approaches. *In vitro Environmental Toxicology-Concepts, Application and Assessment*,
1384 Springer, Cham (157): 1-58.

1385 Wang J., Trentham-Dietz A., Hemming J.D., Hedman C.J., Sprague B.L. (2013). Serum factors and clinical
1386 characteristics associated with serum E-Screen activity. *Cancer Epidemiology and Prevention Biomarkers* 22(5):
1387 962-971.

1388 Wang S., Paris F., Sultan C.S., Song R.X.D., Demers L.M., Sundaram B., Settlage J., Ohorodnik S., Santen R.J.
1389 (2005). Recombinant cell ultrasensitive bioassay for measurement of estrogens in postmenopausal women. *The*
1390 *Journal of Clinical Endocrinology & Metabolism* 90(3): 1407-1413.

1391 Wangmo C., Jarque S., Hilscherová K., Bláha L., Bittner M. (2018). In vitro assessment of sex steroids and related
1392 compounds in water and sediments—a critical review. *Environmental Science: Processes & Impacts* 20(2): 270-
1393 287.

1394 Widschwendter M., Lichtenberg-Frate H., Hasenbrink G., Schwarzer S., Dawnay A., Lam A., Menon U.,
1395 Apostolidou S., Raum E., Stegmaier C., Jacobs I.J., Brenner H. (2009). Serum oestrogen receptor α and β

1396 bioactivity are independently associated with breast cancer: a proof of principle study. *British Journal of Cancer*
1397 101(1): 160-165.

1398 Wielsøe M., Bjerregaard-Olesen C., Kern P., Bonfeld-Jørgensen E.C. (2018). Receptor activities of persistent
1399 pollutant serum mixtures and breast cancer risk. *Endocrine-Related Cancer* 25(3): 201-215.

1400 Wilson C.A., Heinrichs C., Larmore K.A., Craen M., Brown-Dawson J., Shaywitz S., Ross J., Klein K.O. (2003).
1401 Estradiol levels in girls with Turner's syndrome compared to normal prepubertal girls as determined by an
1402 ultrasensitive assay. *Journal of Pediatric Endocrinology and Metabolism* 16(1): 91-96.

1403 Wilson V.S., Bobseine K., Gray L.E. (2004). Development and characterization of a cell line that stably expresses
1404 an estrogen-responsive luciferase reporter for the detection of estrogen receptor agonist and antagonists.
1405 *Toxicological Sciences* 81(1): 69-77.

1406 Wong S.P., Li J., Shen P., Gong Y., Yap S.P., Yong E.L. (2007). Ultrasensitive cell-based bioassay for the
1407 measurement of global estrogenic activity of flavonoid mixtures revealing additive, restrictive, and enhanced
1408 actions in binary and higher order combinations. *Assay and Drug Development Technologies* 5(3): 355-362.

1409

1410

1411

1412

1413

1414

1415

1416

1417

1418

1419

1420

1421

1422

1423

1424

1425

1426 **11. Table captions**

1427 **Table 1.** Studies applying estrogenic activity assay as estrogen quantification and/or biomarker
1428 of estrogenic status.

1429 Footnotes:

1430 AroER tri-screen cells = breast cancer MCF-7 variant without endogenous ER expression (C4-
1431 12) transfected with these plasmids: pTomo-ER α vector or pTomo-ER β vector, pCHGP-2,
1432 pCMV-G, pCMV-rev, pGL4.26 [luc2/minP/Hygro] (ERE)₃.

1433 *Arxula adenivorans* = strain G1212 transformed with YRC102-hER-DsRed2 plasmid.

1434 ER α CALUX cells = human osteoblastic osteosarcoma cells (U2-OS) transfected with 3x ERE-
1435 TATA-Luc and pSG5-neo-hER α (Wong et al. 2007).

1436 HeLa transfected = human uterine cervix carcinoma cells (HeLa) stably transfected with
1437 pERE4-Luc_{hygro} and pEGFP-ER α _{neo} or pEGFP-ER β _{neo} (HeLa ER α transfected or HeLa ER β
1438 transfected, respectively).

1439 HELN = human uterine cervix carcinoma cells (HeLa) stably transfected with ERE- β Glob-
1440 Luc-SVNeo and pSG5ER α puro or pSG5ER β puro plasmids (HELN α or HELN β , respectively).

1441 MELN = breast cancer cells (MCF-7) stably transfected with ERE- β Glob-Luc-SVNeo plasmid.

1442 *Saccharomyces cerevisiae* = strain BJ3505 (MAT α , ura3-52, tryp1 Δ 101, lys2-208) transformed
1443 with YEPKB1 and YRPE2 plasmids.

1444 *Saccharomyces cerevisiae*₁ = triply deleted *pdr5 snq2 yor 1* strain transformed with hER α -
1445 ERE-GFP or hER β -ERE-GFP plasmids (Hasenbrink et al. 2006).

1446 T47D-Kbluc = human breast cancer cells (T-47D) transfected with pGL2.TATA.Inr.luc.neo
1447 (Wilson et al. 2004).

1448

1449

1450

1451 **Table 2.** Studies applying estrogenic activity assay as a biomarker of exposure to EDCs.

1452 Footnotes:

1453 BG1Luc4E₂ = human ovarian carcinoma cells (BG1) stably transfected with pGudLuc7.0

1454 (Rogers and Denison 2000).

1455 ER α CALUX cells = human osteoblastic osteosarcoma cells (U2-OS) transfected with 3x ERE-

1456 TATA-Luc and pSG5-neo-hER α (Wong et al. 2007).

1457 MCF-7 transfected = breast cancer cells (MCF-7) transfected with ERE-tk109 luc, ERE2-

1458 tk109 luc, ERE-tk81 luc.

1459 MVLN = breast cancer cells (MCF-7) stably transfected with pVit-tk-Luc and pAG-60

1460 plasmids (Pons et al. 1990).

1461 *Saccharomyces cerevisiae*_2 = yeast genome integrated with human ER and transformed with

1462 plasmid carrying the reporter gene *lac-Z* (plasmid code not specified) (Routledge and Sumpter

1463 1996).

1464 T47D.Luc = human breast cancer cells (T-47D) stably transfected with pEREtataLuc.

1465

1466 **Table 3.** Characteristics of assays for the assessment of estrogenic activity in human biological

1467 samples (Mueller 2004, Kiyama and Wada-Kiyama 2015, Seifert et al. 1999, Soto et al. 2006,

1468 Wangmo et al. 2018, Wagner et al. 2017). Abbreviations of mammalian and yeast cells reported

1469 in table 1 and table 2 (footnotes).

1470

1471 **Table 4.** Detection limits of estrogenic activity assays compared to detection limits of direct

1472 methods for estrogen quantification. Data are expressed as sensitivity for measuring

1473 estrogens/progestagens (direct methods) and as sensitivity for measuring E2 (estrogenic

1474 activity assays). Ns = not specified. Quantitation limits of direct methods for estrogen

1475 quantification are reported in table S.1 (Supplementary Material). Abbreviations of mammalian
1476 and yeast cells reported in table 1 and table 2 (footnotes).